Staphylococcal Enterotoxin B Induced Clonal Anergy in αβ T Cell Receptor Transgenic Mice by Blankson, Joel Nee-Lartey
Rockefeller University
Digital Commons @ RU
Student Theses and Dissertations
1994
Staphylococcal Enterotoxin B Induced Clonal
Anergy in αβ T Cell Receptor Transgenic Mice
Joel Nee-Lartey Blankson
Follow this and additional works at: http://digitalcommons.rockefeller.edu/
student_theses_and_dissertations
Part of the Life Sciences Commons
This Thesis is brought to you for free and open access by Digital Commons @ RU. It has been accepted for inclusion in Student Theses and
Dissertations by an authorized administrator of Digital Commons @ RU. For more information, please contact mcsweej@mail.rockefeller.edu.
Recommended Citation
Blankson, Joel Nee-Lartey, "Staphylococcal Enterotoxin B Induced Clonal Anergy in αβ T Cell Receptor Transgenic Mice" (1994).
Student Theses and Dissertations. 360.
http://digitalcommons.rockefeller.edu/student_theses_and_dissertations/360
 
Staphylococcal Enterotoxin B Induced Clonal Anergy in Cl� T Cell
Receptor Transgenic Mice
A thesis submitted to the Faculty of the Rockefeller University
in partial fulfillment of the requirements
for the degree of Doctor of Philosophy
Joel N. Blankson
February 1994
 
c Copyright by Joel N. Blankson, 1994
 
Table of Contents
Chapter 1. Staphylococcal enterotoxin B induces clonal anergy in
DO 11.1 a transgenic mice
1.1 Introduction 2
1.2 Materials and methods 22
1.3 Results 34
1.4 Discussion 69
Chaper 2. The role of the CD28/B7 pathway in the response of
primary 0011.10 CD4 + T cells to ovalbumin and Staphylococcal
en terotoxin B
2.1 Introduction 85
2.2 Results 91
2.3 Discussion 97
 
Acknowledgements
I would like to thank Dr. Dennis Y. Loh (Washington University School of Medicine, St.
Louis) for a 0011.10 transgenic mouse, and for clonotypic monoclonal antibody (KJ1-
26). TA3-mB7 cells were the kind gift of Dr. Casey Weaver (University of Alabama at
Birmingham). CTLL-2 cells and neutralizing anti-IL4 monoclonal antibody were
generous gifts from Dr. T. Rao and Len Appleman (New York University School of
Medicine). HT-2 cells were from Dr. Yongwon Choi and were maintained and passaged in
his laboratory by Angela Santana. I would like to thank Dr. Jay Valinsky and Harold
Ralph at the New York Blood Center, and Stuart Gezelter, and Una O'Doherty at
Rockefeller University for helping me with FACS analysis. Dr. Ruta Nonacs gave me
protocols for T cell purification and for proliferation assays. Thais Costa gave me a
protocol for the calcium flux assay. Dr. Mercedes Sanchez helped me with FACS analysis
and the calcium flux assay. Jay Wayne spent a lot of his time teaching me how to use the
FACS machine and he also helped me with the computer graphics. Bill Swiggard has been
a great advisor throughout medical and graduate school, and has been my chief technical
consultant. I would like to thank Dr. Michel Nussenzweig and Dr. Ralph Steinman for
being supportive of me and for generously allowing me to use their equipment. I would
like to thank the members of my thesis committee, Dr. Ralph Steinman, Dr. John
Zabriskie, Dr. Yongwon Choi and Dr. Helen Quill (University of Pennsylvania School of
Medicine) for many helpful discussions and for their patience. I would especially like to
thank Dr. Steinman, for the time he has spent with me discussing my project, and for the
great immunology tutorial he ran. Finally I would like to thank my mentor Dr. Stephen
S. Morse; he allowed me to work independently, but at the same time he was always very
supportive of me, and he always went out of his way to assist me when I needed help. I
have learned a great deal of science from him and I will always be grateful for the
opportunity he gave me.
 
ABSTRACT. Superantigens such as staphylococcal enterotoxin B (SEB) have been
widely used to study T cell tolerance. While both clonal deletion and apparent anergy
have been described in response to superantigens, it has not been clear whether true
anergy occurs, or whether the most reactive T cells are selectively deleted, leaving
less reactive clones. To address this question, the response of an essentially
monoclonal population of primary T cells to a superantigen was followed by priming
ovalbumin (OVA) specific (X� T cell receptor transgenic mice with SEB. Cells from
these mice appeared to be anergic in that they were hyporesponsive to OVA peptide as
well as to SEB. The anergic cells could respond to PMA and ionomycin suggesting that a
proximal signal transduction step was affected. Cells from transgenic mice primed
with OVA peptide, the specific antigen, were not anergic. Thus, in this system, the
ability to tolerize mature T cells appears to be a property unique to superantigens. To
address the question of whether superantigen induced tolerance was due to T cell
activation in the absence of costimulation, we examined the effect of the CD28/B7
pathway on the response of T cells to SEB and OVA. The T cell response to both OVA and
SEB was enhanced by antibodies to the CD28 coreceptor suggesting that CD28/B7
mediated costimulation plays a role in the signal transduction pathways coupled to the
two types of antigens.
 
Chapter 1.1 (Introduction)
The variable region of T cell receptor is made up from the products of five gene
segments from the variable (V), diversity (D), and joining (J) gene families; Va. and Ja.
make up the a. chain, whereas V�, D�, and J�, contribute to the � chain (reviewed in 1).
Each chain is generated by the random rearrangement of these non contiguous gene
segments (1). Because this is a random process, there is nothing to prevent the
generation of T cells with receptors specific for self antigens. Tolerance can be defined as
the process by which potentially self reactive lymphocytes are silenced. There have been
three major hypotheses proposed to explain how the immune system aquires tolerance to
self antigen. They are as follows:
1. Clonal deletion. This theory was first proposed by Lederberg (2) as a modification of
Burnet's clonal selection theory (3). The theory proposed that immature cells react
differently from mature lymphocytes in response to the engagement of their receptors:
immature cells would be deleted whereas mature cells are activated. Thus lymphocytes
with self reactive receptors would eventually come into contact with self antigen as they
developed and this would result in their selective deletion.
2. Clonal anergy. In this view, self reactive cells were not physically eliminated. Instead
they were functionally inactivated or anergized. Evidence for this hypothesis came from
studies demonstrating that B cells in fetal mice could be tolerized without being
physically deleted (4).
3. Suppression. This hypothesis suggested that self reactive lymphocytes were held in
check by suppressor cells or suppressor factors. This hypothesis was supported by
experiments showing that when lymphocytes from animals tolerized to a given antigen
were transferred into naive animals,they prevented the hosts' lymphocytes from reacting
to the tolerizing antigen (5,6).
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It has been very difficult to distinguish between these hypotheses in T cells because it
has not been possible to physically identify a primary T cell that was specific for any
given antigen. Instead, T cell antigenic specificity was defined functionally by a response
to the antigen. Thus, in the absence of a response, one could not determine whether self
reactive cells had been deleted or were present but not reactive due to either anergy or
suppression. The discovery of superantigens which activate clonal populations of T cells
has therefore had major implications in the study of T cell tolerance.
There are two major groups of confirmed superantigens, toxins from different bacteria
including staphylococci and streptococci, and proteins encoded by the endogenous and
exogenous mouse mammary tumor viruses.
The best way to describe a superantigen is to compare it with the so called conventional
antigens. Before a conventional extracellular protein antigen can activate a T cell it must
first be processed into peptides by antigen presenting cells (7) which are then presented
in a specialized cleft present in the major histocompatibility complex (MHC) class II
proteins on the cell surface. The bacterial toxins are also proteins but they apparently do
not have to be processed prior to presentation; in fact pretreating toxins with proteases
tends to reduce the response to these antigens (8). The toxins also tend to bind differently
to MHC class II molecules; they do not appear to bind to the peptide cleft since mutations
in this region affects T cell responses to peptides but not to superantigens (9).
The most distinctive feature of a superantigen is the manner in which it is recognized
by T cells. The trimolecular interaction between conventional peptide, MHC, and TCR
involves to some extent all five gene segments of the variable region of the TCR,
especially the hypervariable region made up from the junctional segments (10). Because
of the specificity of this interaction, very few T cells will react to any given conventional
antigen. Superantigens, on the other hand, interact primarily with the V� gene product
(11-13) and can therefore activate T cells in a V� specific manner. Because this
interaction requires only V� which may be shared by a large number of T cells bearing
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different specificities for conventional antigens, many more T cells will respond to a
superantigen than to a conventional antigen. There are approximately 20 different V�
families in the mouse and it thus follows that any given superantigen will activate
roughly 5% of the entire T cell repertoire.
The viral superantigens were first described by Festenstein as undefined antigens
present in certain strains of mice that would induce powerful immune responses in other
mice even if the two strains had the same MHC haplotype (14). He named these antigens
minor lymphocyte stimulatory (Mis) antigens. It has since been shown that Mis and Mis
like antigens are encoded for by the open reading frame (ORF) present in the 3' long
terminal repeat sequence of the endogenous and exogenous mouse mammary tumor
viruses (MMTVs) (15-21).
The sequences of these viral superantigens are very similar except for 20-30 residues
at the carboxy terminal which determine the specifity for V�s (22-25). In vitro
translation studies have shown that the ORF proteins are type II integral membrane
proteins with the carboxy terminus present at the cell surface (26-28). This correlates
with the finding that the carboxy terminus of the viral superantigens determine V�
specificity, as this region would be expected to interact with T cells. Monoclonal
antibodies (mAbs) have been recently developed to the ORF protein of MMTV and have
been shown to block T cell activation (29-31). In one study the mAb was used to
demonstate that the superantigen was expressed on the surface of activated B cells but not
on resting spleen cells, thymocytes, or activated T cells (29). In addition it was shown
that the superantigen probably exists on the cell surface as a processed 18.5 kilodalton
protein.
Because superantigens stimulate T cells primarily through the V� element of the TCR,
the development of mAbs to different V� segments enabled investigators to physically
identify superantigen reactive T cells and this revolutionized the study of tolerance. In
fact the first direct evidence for clonal deletion came from work done with superantigens.
 
Clonal deletion
Kappler et al. demonstrated that >90% of all hybridomas tested that expressed Vp 17a as
part of their TCR would respond to an endogenous superantigen (most likely an MMTV)
presented by the MHC class II I-E molecule (32). This superantigen has still not been
mapped but it appears to be present in all strains of mice (33), is presented exclusively
by the I-E molecule, and is expressed in B cells but not in macrophages or fibroblasts
(34) .
Kappler et. then used a mAb they developed to Vp17a to compare I-E+ and I-E- strains
of mice. They reasoned that since the I-E molecule (and the endogenous superantigen it
presented) was a self antigen, I-E+ mice should be tolerant to this molecule. This turned
out to be the case; peripheral Vp 17a T cells were present in I-E- mice but not in I-E+
mice (35). Furthermore, when I-E- mice were mated to I-E+ mice, the F1 mice had no
mature Vp17a T cells. When these F1 mice were mated to I-E- mice, it was found that all
the F-2 mice that had inherited the I-E molecule had low levels of Vp 17a cells whereas
their I-E- littermates had normal levels of these cells (35).
On comparing the thymuses of I-E- and I-E+ mice, it was found that both sets of mice
had roughly equal numbers of immature cells expressing low levels of Vp 17a. I-E+ mice
however, had almost no mature Vp 17a thymocytes whereas I-E- mice did (35). Thus it
appeared that immature thymocytes expressing a self reactive receptor were not allowed
to complete development and leave the thymus.
This was strong evidence for intrathymic clonal deletion and it opened up a whole new
field of using superantigens to study tolerance. Similar techniques were used by Kappler
et al. to demonstrate that Vp8.1 T cells reacted to the endogenous superantigen Mls-1
(36). This antigen has since then been shown to be the product of mtv-7 (18).
MacDonald et al. showed that this same superantigen reacted with Vp6 cells (37), and
both groups demonstrated deletion of these Vp types in Mls-1 + (Mls-1 a) but not Mls-
1- (Mls-1 b) mice. Another Mis antigen, Mls-2 ,was shown to interact specifically with
5
 
V �3 cells and deletion of these cells was demonstrated in Mls-z+ (Mls-2a) mice
(38,39).
Clonal anergy
In addition to clonal deletion, clonal anergy has been shown to be an important
mechanism for inducing tolerance. Much of the initial work in this field resulted from
work done with bone marrow radiation chimeras. These chimeras are based on the finding
that cells derived from the bone marrow, such as lymphocytes and dendritic cells, are
relatively susceptible to radiation whereas thymic stromal epithelial cells are relatively
radioresistant. Mice can therefore be irradiated to eliminate their bone marrow derived
cells and reconstituted with cells from a different genetic background.
Two groups independently made chimeras where the Mls-1 and I-E associated
superantigens were present only on the radioresistant thymic epithelial cells (40,41).
V�6 and V�17a cells, derived from the bone marrow of Mls1 band I-E- donor mice, were
not deleted but appeared to be functionally tolerant as they did not proliferate in response
to Mls-1 a, I-E+ spleen cells in vitro. In addition to this, the cells did not respond to
immobilized anti V�6 or V� 17 mAbs implying that these cells were anergic.
Interestingly, the addition of exogenous IL-2 could partially reverse anergy, suggesting
that I L-2 secretion was a major defect in these cells.
This is very similar to the in vitro clonal anergy described by Ron Schwartz and
colleagues. In that model, anergy is induced in T cell clones by engaging the TCR in the
absence of a second or costimulatory signal (42). This two signals versus one signal
hypothesis was proposed by Bretscher and Cohn as an explanation for B cell tolerance
(43). In the most physiological variation of this model, planar membranes containing
purified MHC class II molecules pulsed with specific peptide were shown to induce a long
lasting state of anergy in T cell clones (44). The costimulatory signal appears to be
important for the secretion of IL-2 which acts as an autocrine growth factor that is
essential for T cell proliferation.
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It was argued that the anergy seen in the bone marrow chimeras was due to the fact that
the thymic epithelial cells could provide the first signal (in this case the superantigen
and MHC class II) but not the second costimulatory signal. This hypothesis was supported
by earlier work by lorenz and Allen, where it was shown that thymic epithelial cells
could present peptides to hybridomas but could not induce proliferation in T cell clones,
implying that they were lacking an essential costimulatory signal (45).
T cell receptor transgenic mice
In order to study tolerance in a system with a relatively homogenous population of T
cells, several investigators generated � and a.� T cell receptor (TCR) transgenic mice and
then looked at their response to endogenous superantigens. Pircher et al made TCR
transgenic mice, >90% of whose T cells expressed the Mls-1 reactive V�B.1 segment, and
then crossed them onto an Mls-1 a background (46). They found that lymph nodes (lNs)
from these mice contained one third the number of cells found in Mls1 b mice. The
remaining cells generated diminished cytotoxic T lymphocyte (CTl) responses to
allogeneic target cells. The response could be partially restored by the addition of cuture
supernatant from concanavalin A (Con A) stimulated T cells (presumably containing Il-
2 and other cytokines). The CTl response to vaccinia virus infected target cells was also
reduced but surprisingly, the mice could produce T cell dependent neutralizing IgG to
vesicular stomatitis virus just as efficiently as Mls-1 b transgenic mice. It is therefore
likely that the T cells were defective in producing Iymphokines needed for a CTl response
but could produce factors needed to help B cells.
Blackman et al. generated similar V�B.1 TCR transgenic mice and bred them onto Mls-
1a and Mls-1b backgrounds (47). They found almost no deletion of C04 cells and no
deletion of COB cells in Mls-1b mice. Many (20-50%) of all C04 cells from Mls-1a
mice appeared to be pan anergic in that they did not respond well to Mls-1 a spleen cells,
staphylococcal enterotoxin B (SEB, a bacterial toxin superantigen that stimulates V�B+ T
cells), anti TCR mAbs, or concanavalin A. COB cells were not anergic in that they
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proliferated as well as cells from Mls-1 b mice. Interestingly mature CD4 thymocytes
were not anergic, implying that cells were anergized in the periphery.
The genes for the a and J3 chains from a lymphocytic choriomenigitis virus ,(lCMV)
specific CD8 T cell clone were used to make aJ3 TCR transgenic mice (48). The J3 chain
was VJ38.1 and therefore the T cells were specific for Mls-1 a as well as lCMV. When
these mice were bred on an Mls-1 a background, 65% of the mature COB cells were
deleted. The remaining cells were not anergic and could proliferate in response to lCMV
infected peritoneal macrophages and specifically lyse lCMV infected target cells. This
might correspond with the finding of Blackman et al, that CD8 T cells were not anergized
by Mis (47).
In contrast to the moderate degree of tolerance seen in response to Mis, the
investigators demonstrated that when the mice were infected with lCMV at birth, there
was a marked deletion of immature thymocytes and a 90% reduction in the number of
peripheral CD8 T cells (48). Only one third of the remaining CD8 T cells expressed the
transgenic J3 chain and there was no proliferative or CTl response to infected cells. It
therefore appeared that the conventional antigen was better able to induce tolerance than
the superantigen, but this could be due to either a dose effect or to a greater affinity of
the original clone for its specific antigen than for the superantigen.
Berg et al, generated both J3 and aJ3 transgenic mice using transgenes from a hybridoma
specific for cytochrome c (49). The J3 chain was VJ33 and therefore reactive to Mls-2.
Both sets of transgenic mice were bred on Mls- and Mls- backgrounds. In the Mls-2a
transgenic mice, less than 10% of the IN cells were VJ33+ compared to the 70-90%
found in Mls- transgenic mice. The investigators did not report the number of peripheral
T cells present in the Mls-2a aJ3 transgenic mice but there was much more intrathymic
deletion in these mice than in J3 transgenic mice due to increased TCR expression. No
functional tests were performed so it is not known if the remaining cells in either line
were anergic.
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MMTV transgenic mice
When it had been shown conclusively that the Mis and Mis related superantigens were
encoded for by endogenous MMTV, two groups made mice transgenic for exogenous MMTVs
to further study the role of these viruses in T cell development. In one study, transgenic
mice expressing either the entire genome of mtv(GR) or just the ORF present in the 3'
long terminal repeat were made (21). This MMTV is located on chromosome 2 of GR mice
but is capable of producing infectious virus. The superantigen produced by this virus
stimulates V�14 T cells. The mice used in the study did not have an endogenous equivalent
of this MMTV and therefore had normal numbers of V� 14 cells. Mice expressing either
transgene deleted their V� 14 cells. This was direct evidence that the MMTVs were
responsible for V� specific deletion in mice. Interestingly mice transgenic for the mutant
virus MMTV C3H-K did not delete their V�14 cells. Compared with GR, this mutant virus
has several point mutations as well as substitution of LTR sequences resulting in a major
difference in the last 32 residues of the ORF gene. This finding correlates with the
observation that the C terminal residues determine V� specificity.
In a similar study, Golovkina et at, made transgenic mice expressing the ORF from
MMTV C3H (50). This virus is transmitted through milk (17) and the ORF present in
the 3' LTR has been shown to encode for a superantigen specific for V� 14 and V� 15 T
cells(20). It was found that mice expressing this transgene deleted their V�14 cells and
that in different transgenic lines the degree of deletion correlated with the level of
transgene expression. Interestingly, mice expressing high levels of the ORF transgene did
not become infected with the exogenous virus present in their mother's milk. This was
evidence that the exogenous virus utilized V� 14 T cells in its infectious pathway
(probably to transmit the virus to the mammary gland) and suggested that by deleting
specific V� populations, endogenous viruses may help protect mice from infection with
exogenous viruses that had similar superantigen specificities.
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Cell types involved in Mis mediated deletion
These transgenic models were useful in demonstrating tolerance to endogenous
superantigens but they did not address the question of which cells were actually involved
in tolerance induction. Before the exact nature of the Mis superantigens was known,
several investigators performed adoptive transfer studies where specific subpopulations
of cells from Mls+ donors were transferred into Mls- hosts.
Webb and Sprent injected into neonatal Mls-1 b mice highly purified C04 cells, COB
cells, B cells or T cell depleted spleen cells (51). The mice were then examined two to
seven weeks later for signs of tolerance to Mls-1. COB T cells were 50-100 times more
efficient than C04 T cell or B cells in inducing clonal deletion of V�6 cells and in inducing
tolerance to Mis -1 a spleen cells. This was an unexpected finding since COB T cells do not
express MHC class II antigens. It was assumed that either Mis antigen was transferred
from COB T cells to traditional antigen presenting cells (APCs) or that there might be
corecognition of Mis present on COB T cells and MHC class II molecules on APCs.
In similar experiments, Inaba et al, injected either B cells or splenic dendritic cells
from Mls-1 a mice directly into the thymuses of Mls-1 b neonatal mice (52). Thymic but
not splenic B cells were tolerogenic in that they were able to delete V�6 thymocytes and
induce functional tolerance as measured by a graft versus host reaction. Interestingly
dendritic cells were able to induce functional anergy but not clonal deletion of V�6
thymocytes. This finding confirmed prior studies that had shown that B cells and not
dendritic cells were the major presenters of Mis in vitro (53, 54).
Mazda et al. used a different system to adress the same question. Fetal thymus organ
cultures were used to culture precursor thymocytes from Mls-1 b mice in
deoxyguanosine treated Mls1-b thymuses (this treatment specifically kills bone marrow
derived cells) in the presence of different Mls-1 a APCs (55). It was found that neither
8 cells nor dendritic cells alone could induce clonal deletion of V�6 thymocytes. Efficient
deletion was only seen when Mls-1 a B cells were injected with Mls-1 b dendritic cells.
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This raised the possibility that the Mis antigen was being transferred from B cells to host
dendritic cells which could then mediate clonal deletion. Dendritic cells from Mls-1 a
mice probably could not induce deletion by themselves simply because they did not have
sufficiently high levels of the Mis antigen.
Intrathymic tolerance to a bacterial superantigen
Jenkinson et at, used a similar fetal thymic organ culture system to demonstrate that
that SEB could induce the specific deletion of V�8 thymocytes (56). Apoptosis or
programmed cell death was implicated as the mechanism of cell death as oligonucleosomal
DNA fragments were found in SEB treated but not control cultures. The same group later
showed that dendritic cells were much more efficient than thymic epithelial cells in
inducing SEB mediated clonal deletion (57).
White et at, demonstrated that the bacterial toxins could induce intrathymic tolerance
in vivo as well as in vitro (58). Neonatal mice were injected with SEB every other day
from birth to day 15. A partial deletion of immature thymocytes as well as an almost
complete deletion of mature thymocytes expressing SEB reactive V�s was seen. It was also
shown that this same toxin would activate mature splenic T cells in vitro. It thus
appeared that triggering T cells at different stages of development had different
consequences; mature T cells were activated whereas immature thymocytes were deleted.
This work was also the first direct evidence that a foreign antigen could induce tolerance
in neonates by causing the deletion of reactive T cells.
Peripheral tolerance
In a" of these models, the tolerizing superantigen was either expressed in the thymus
or could somehow be transported to the thymus. While these models were crucial in
defining the mechanims involved in intrathymic tolerance, they did not address the
question of how T cells became tolerant to antigens that were expressed only outside the
thymus. Several investigators designed experiments using superantigens to address this
question of peripheral tolerance.
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1. Tolerance in athymic mice
Two groups independently compared the T cell repertoires of Mls+ nude mice to
euthymic mice of the same strain (59,60). Nude mice have an epithelial defect which
prevents cells in the third and fourth pharyngeal pouches from developing into the
thymic anlage. In spite of not having a functional thymus, these mice develop low
numbers of (l� T cells in the periphery. It was found that nude mice but not euthymic
controls had significant percentages of T cells with V�� specific for Mis and I-E associated
superantigens. It therefore appeared that a thymus was essential for proper clonal
deletion of self reactive T cells. Despite the presence of T cells with potentially self
reactive receptors, nude mice do not suffer from autoimmune diseases. A later study
revealed that T cells from nude mice could not respond to the bacterial toxin staphlococcal
enterotoxin A (SEA) (61). This superantigen specifically stimulates V�3 and V�11 cells.
Both of these V�s also react to endogenous superantigens and are deleted in euthymic but
not athymic mice (59,60). The inability of these V�s to react with SEA suggested that
they were probably anergic.
Neonatally thymectomized mice were also used as a model to study peripheral tolerance.
Like nude mice, these mice had high percentages of T cells with self reactive V�s (62),
but unlike nude mice they eventually develop a wide array of autoimmune disease (63).
It was thus felt that the self reactive T cells might be responsible for the observed
autoimmunity. However work by Jones et al, demonstrated that the T cells bearing self
reactive receptors were anergic in that they could not proliferate in response to
immobilized V� specific mAbs (64). The two models suggested that while clonal deletion
did not occur in the absence of a thymus, peripheral anergy existed as a backup
mechanism of tolerance induction.
2. I-E transgenic mice
In a somewhat different approach, Lo et at, made transgenic mice expressing the I-E (l
and � chains only in non lymphoid organs. The rat insulin or the rat elastase promoter
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were used to target the transgenes to pancreatic � (65) or acinar cells (66)
respectively. T cells from both sets of mice appeared to be tolerant to I-E+ spleen cells
and no T cell mediated autoimmune disease was seen.
There is some question as to whether the transgenic I-E molecules were presenting
endogenous superantigens or allogeneic peptides. The endogenous superantigen presented
by the I-E molecule stimulates T cells bearing the V� 17a segment. Whereas no deletion
of V� 17a cells was seen in either line (65,66), T cells from � cell transgenic mice but
not from acinar cell transgenic mice were tolerant to immobilized anti V� 17 mAb (67).
It thus appeared that the tolerance seen in the acinar transgenic mice was to allogeneic
peptides and not to the endogenous superantigen. A possible explanation for the difference
seen in the two transgenic lines is that acinar cells might not express the endogenous
superantigen and as such T cells in these mice may have never been exposed to it.
There is also some question regarding the leakiness of both promoters. Although
transgenic mRNA was not seen in the thymuses of either line, the thymocytes were
surprisingly tolerant to I-E+ spleen cells (65,66). Therefore these mice may not be a
good model for peripheral tolerance as one cannot be sure at what stage the T cells first
came into contact with the antigen in question.
3. Peripheral tolerance to Mis
In a different model, Rammensee et al, injected Mls-1 a spleen cells into adult Mls-1 b
mice (68). Surprisingly, T cells from the recipient mice became tolerant to the Mls-1 a
spleen cells; they could neither proliferate nor secrete IL-2 in response to these cells in
vitro but could respond normally to third party alloantigens. Anergy appeared to be the
mode of tolerance as there was no deletion of Mls-1 reactive V�6 cells, and suppression
was ruled out by cell mixing experiments. The anergic V�6 cells were able to express the
IL-2 receptor a. chain when stimulated with Mls-1 a spleen cells but the addition of
exogenous IL-2 did not restore proliferation. Thus it appeared that Mis could tolerize
mature T cells as well as thymocytes. It should be noted that in the previously described
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models of peripheral tolerance, the T cells devloped in the presence of the tolerizing
antigen. In this model however it is significant that T cells that had matured in the
complete absence of the Mis antigen were rendered tolerant after their initial contact.
Webb et al. performed a similar experiment but used thymectomized mice in order to
keep the peripheral T cell repertoire stable (69). Purified Mls-1 a B cells, CD8 T cells,
and T cell depleted splenocytes were all able to tolerize Mls-1 b mice. However in
contrast to Rammensee et aI., the investigators observed a marked expansion followed by
partial deletion of V�6+ CD4 cells; these cells expanded from roughly 10% to 40% by
day 4 and then decreased to 2-3% by day 22. Viable cells were required to induce the
observed tolerance as irradiated Mls-1 a cells failed to induce either clonal deletion or a
decrease in the proliferative response to Mls-1 a spleen cells. This was the first direct
evidence of clonal deletion of mature peripheral T cells and the authors concluded that
tolerance could be the endpoint of a strong immune response.
Peripheral tolerance to Staphylococcal enterotoxin B
Two groups independently demonstrated that the the bacterial superantigen SEB could
also induce anergy in mature T cells (70,71). In one study, adult mice were immunized
intravenously with different doses of SEB. CD4 cells but not CD8 cells were found to be
anergic to the superantigen in vitro (70). The degree of anergy was proportional to the
dose of SEB administered. CD4 cells were defective in Il-2 production and proliferation,
but surprisingly, they were able to specifically lyse SEB pulsed target cells in CTl
assays (70). Rellahan et al, demonstrated that cells from SEB primed mice were non
responsive to immobolized V�8 mAb as well as to SEB (71). It was found that V�8 cells
were able to express the IL-2 a receptor in response to SEB, but exogenous IL-2 did not
restore proliferation (71). This finding was similar to the results of experiments of
Ramennsee et at, on Mis induced peripheral anergy, and suggested that there might be a
defect in IL-2 responsiveness as well as IL-2 secretion.
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It was later found that the in vivo response to SEB was quite similar to the response to
Mis; there was an initial clonal expansion followed by partial deletion of Vf38 T cells
(72,73). Two independent studies demonstrated that when cells at the clonal expansion
phase were cultured overnight at 37 C, the Vf38 cells declined to control levels (72,73).
One study suggested that programmed cell death was involved in deletion, as genomic DNA
fragments (although not in an oligonucleosomal pattern) were seen in Vf38 but not in Vf36
cells (72).
The presence of DNA fragmentation in cells from SEB primed mice was confirmed by
another group (74), but it was found that inhibitors of protein and RNA synthesis failed
to prevent this DNA fragmentation, significant because these agents have been shown to
prevent some forms of apoptosis in cell lines. Only zinc, which blocks activation of
endonucleases and aurintricarboxylic acid, which directly inhibits endonuclease activity,
could prevent this DNA fragmentation (74). DNA fragmentation is also seen in cells from
Mls-1 b mice primed with Mls-1 a cells (75) but in both models the cells first have to
be cultured in vitro at 37 C. DNA fragmentation is never seen in cells taken ex vivo
immediately from superantigen primed mice implying that either apoptotic cells are
cleared very rapidly in vivo, or apoptosis might not really be the mechanism of cell death
in vivo.
The reversibility of anergy
1. The role of time! persistance of antigen
Migita and Ochi recently demonstrated that SEB induced anergy is gradually reversed
with time (76). Cells from thymectomized mice primed with SEB four months prior to
sacrifice could proliferate in response to SEB just as efficiently as cells from control
mice. The investigators used Thy1.1 IThy1.2 chimeras to rule out the possibility that the
observed proliferation was due to the selective outgrowth of a population of non anergic
cells. The investigators however did not determine if the IL-2 secretion response was
restored as well.
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This reversal of anergy with time may be due to the gradual loss of SEB in vivo as
Ramsdell and Fowlkes have shown that the persistence of superantigen is required for the
maintenance of anergy (77). Using the previously described bone marrow radiation
chimera (40), it was found that taking T cells (derived from the bone marrow of Mls-
1 b, I-E- mice) from the irradiated Mls-1 a, I-E+ hosts and "parking" them into
irradiated Mls-1 b, I-E- mice reversed anergy by 20 days post transfer. Specifically
the T cells could now respond to immobilized anti V�6 and V� 17 mAbs. The same effect
was seen when purified T cells were cultured in vitro in the presence of interleukin-7
as a trophic factor.
2. The role of IL-2
Lack of IL-2 production has been shown to be a major defect in anergic T clones. T cells
from mice treated with either SEB (70) or Mls+ cells (68) produce significantly less
IL-2 than control cells in response to the respective superantigen. The addition of
exogenous I L-2 does not fully restore proliferation (68,71) suggesting that other
defects are present.
I L-2 however does appear to at least partially reverse anergy of potentially self
reactive T cells in nude mice. In one study it was shown that these cells would undergo
clonal expansion in response to the bacterial superantigen SEA only in the presence of
IL-2 (61). Based on this work, Gutierrez-Ramos et at. treated nude mice with either a
recombinant vaccinia virus expressing the human IL-2 gene or wild type vaccinia virus
as a control (78). It was found that T cells with self reactive receptors in the mice
treated with the recombinant virus were now able to proliferate in response to
immobilized V� specific mAbs and the mice developed such signs of autoimmunity as
erythroleukopenia, rheumatoid factors and autoantibodies to double stranded DNA. No
autoimmune disease or reversal of T cell anergy was seen in mice treated with the wild
type virus. While there is no evidence that the activation of the self reactive T cells was
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responsible for the observed autoimmune disease, this study clearly demonstrated that
IL-2 could reverse some forms of anergy when given in vivo as well as in vitro.
In contrast to the results seen with nude mice, treating SEB primed mice with the same
recombinant virus did not reverse anergy (74). In fact it had no effect at all on the
kinetics or magnitude of either clonal expansion or deletion. This finding suggests that not
all forms of peripheral anergy have the same underlying defect, and it correlates with
the inability of exogenous IL-2 to reverse SEB induced anergy in vitro (71).
3. Infection with parasites
Rocken et al. infected either control or SEB primed mice with Nipostrongylus
brasiliensis, a nematode that induces T cell proliferation and interleukin-4 (IL-4)
secretion in vivo (79). It was found that infection resulted in an increase in the absolute
number of V�8 T cells in the mesenteric LNs of both control and SEB treated mice
implying that the anergic cells were capable of proliferating in response to the nematode.
Furthermore, CD4 cells from both sets of infected mice produced high levels of IL-4 in
response to in vitro challenge with either SEB or immobilzed V�8 mAb. Cells from
infected SEB primed mice however could still not secrete IL-2 in response to either
mitogen. While it appears that the nematode was able to partially reverse SEB induced
anergy, it is also possible that a subset of non anergic V�8 cells proliferated in response
to the nematode and differentiated into Th-2 type cells which can secrete IL-4 but not
IL-2.
Factors affecting the degree of deletion or anergy
1. Cyclosporin
Vanier and Prud'homme injected different doses of the immunosuppresive drug
cyclosporin A (CsA) into thymectomized BALB/c (Mls-1 b) mice that had been primed
with either SEB or with Mls-1 a spleen cells (80). They found that high doses of the drug
(50mg/kg/day l.p.) enhanced V� specific deletion in both models. Paradoxically, it was
found that although mice treated with SEB and CsA had slightly fewer V�8 T cells than
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mice treated with SEB alone, cells from these mice were not anergic to SEB. In other
words the coinjection of CsA appeared to 1) increase the degree of V�8 T cell deletion and
2) abrogate anergy to SEB. This prevention of anergy but not the increased V� specific
deletion was still seen when lower doses of CsA (> 12.5mg/kg/day) were given.
It is difficult to understand why CsA would on one hand enhance clonal deletion and yet
on the other abrogate anergy. These results would suggest that deletion and anergy may be
independent of each other and have completely different mechanisms of actions. CsA
blocks IL-2 secretion and has effects on other cytokines as well (81). It is interesting
that a drug that blocks IL-2 secretion would prevent rather than enhance anergy, a state
associated with decreased IL-2 production. It should be noted that in a prior study by
another group, comparable doses of CsA had no effect at all on either deletion or anergy
in SEB treated mice (74).
2. Cortisone
Lusssow et al. demonstrated that hydrocortisone could enhance the SEB mediated
deletion of V�8 T cells in thymectomized mice (82). Furthermore V�8.1 TCR transgenic
mice bred on an Mls-1 a background deleted almost all of their remaining T cells when
they were treated with cortisone. This effect was not seen in V�8.1 TCR Mls-1 b
transgenic mice or in control mice. This work suggested that mature T cells that had
interacted with a superantigen but had escaped deletion were susceptible to cortisone
whereas control T cells were not.
3. BcI-2 oncogene
The bcl-2 protooncogene encodes a protein that appears to be associated with the inner
membrane of mitochondria (83). It has been found that the overexpression of this gene
prevents the death of certain cell lines in response to the withdrawal of growth factors
(84). Transgenic mice have been made that express bcl-2 under the regulation of an
immunoglobulin enhancer (85). Some strains of these transgenic mice express bcl-2 in
T cells as well as B cells. Thymocytes from these mice survive longer than normal
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thymocytes in response to agents such as sodium azide, dexamethasone and 'Y irradiation
(86) .
When these mice were primed with SEB, V�8 peripheral T cells expanded to levels that
were 1.5-3 fold higher than found in SEB primed non transgenic mice (86). The
activated V�8 T cells did not decline as rapidly or to the same extent as did cell from non
transgenic mice. Interestingly, the bcl-2 transgene had no effect on anergy induction.
This might suggest that anergy and clonal deletion have two different mechanisms and that
the bcl-2 oncogene plays a role in one but not the other. Alternatively, it might mean that
anergy and deletion are two steps on the same pathway, and that bcl-2 is involved in a
step somewhere after anergy induction but before clonal deletion.
Role of other TCR elements in superantigen reactivity
Vacchio et al. designed experiments to determine whether the Va segment contributed to
the reactivity of V�6 cells to Mls-1 (87). Four Va specific mAbs were developed and
each was used in two color flow cytometric (FACs) analysis with the V�6 mAb. T cells
from Mls-1 b mice were then incubated with Mls-1 a stimulator cells. As expected there
was a clonal expansion of V�6 T cells in response to Mls-1 but somewhat suprrisingly,
there was a skewing of the v« subtypes present on the V�6 cells. In C3H and BALB/c
mice, there was a consistent decrease in the percentage of V�6 T cells expressing either
Va2 or v« 8. In B10.A mice, there was a relative increase in the percentage of V�6 cells
that were Va11 + and relative decreases in cells that were either Va3+ or Va8+. No such
skewing of Va subtypes was seen in response to immobilized V�6 mAb. This work
suggested that Mis recognition was influenced by vo. expression as well as by V�
expression.
Smith et al. further demonstrated that a chains contribute to superantigen reactivity.
The investigators generated 176 hybridomas from V�8.1 mls-1 a TCR transgenic mice
and 120 from V�8.1 Mls-1 b TCR transgenic mice (88). They then determined the Mls-1
reactivity of each hybridoma and correlated this with the Va gene expressed. Of the
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hybridomas from Mls-1 b mice, 43% were Mls-1 reactive with a good correlation
between Mis reactivity and the Va gene expressed. In particular, Va 11.1 cells were
generally Mls-1 reactive whereas Va2, Va8 and Va11.3 cells were generally not Mls-1
reactive. Furthermore there was a skewing of v« usage in hybridomas generated from
Mls-1 a transgenic mice. The non Mis reactive Va2 and Va8 hybridomas were
overrepresented whereas Mis reactive v« 11 cells were completely absent in these mice.
Almost all of the hybridomas from both sets of mice were SEB reactive, but the dose
required to induce one half the maximal stimulation varied by more than a thousand fold.
This is relevant since decreases observed in SEB induced anergy usually ranges from 50
-90% and could therfore be easily be explained by the selective deletion of V�8 cells with
highly reactive Va subunits.
This v« selective deletion has now been demonstrated in vivo. V�8.1 TCR transgenic
mice were treated with SEB and hydrocortisone to induce deletion. A comparison between
these mice and untreated controls revealed skewing of the v« repertoire; there was a
marked increase in the percentage of Va2 cells and a decrease in the percentage of Va8 T
cells (89).
Taken together, these studies can be interpreted to suggest that priming mice with SEB
may result in the selective deletion of highly reactive T cell clones and that this selective
deletion rather than true clonal anergy might account for some or most of the diminished
response to SEB.
Because this point is essential, one of the main goals of this project was to distinguish
between selective deletion versus true clonal anergy. To do this we collaborated with Dr.
Dennis Loh at Washington University to obtain a� TCR transgenic mice expressing
transgenic TeRs specific for an ovalbumin (OVA) peptide in the context of I-Ad (90).
Both transgenes were obtained from the 0011.10 hybridoma (91) which responds to OVA
323-339 (92). The � chain is V�8 and therefore the cells respond to SEB as well as to
OVA, the specific antigen. A clonotypic mAb, KJ1-26, has been developed to this
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hybridoma. T cells in the 0011.10 transgenic mice that express both a and � T C R
transgenes can be detected with this clonotypic mAb (90) and should all be equally
responsive to SEB.
As will be shown in the Results section, when these mice were primed with SEB,
diminished responses to OVA, SEB, and immobilized clonotypic mAb were seen even
though the number of KJ1-26 cells present was comparable to that found in control
mice. This is consistent with true clonal anergy. The anergic cells were able to respond to
PMA and ionomycin, suggesting that a proximal signal transduction step was affected.
This step however, is probably not calcium mobilization as anergic cells could mobilize
calcium in response to Con A.
To determine whether conventional antigens could also induce tolerance, the transgenic
mice were primed with OVA peptide. Cells from these mice responded normally to SEB and
were hyperresponsive to OVA, suggesting that, at least in this system, superantigens but
not conventional antigens can tolerize mature T cells.
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Chapter 1.2 (Materials and Methods)
Transgenic mice. An 8 week old agouti male, heterozygous for the 0011.10 a and f3
transgenes, was received from Dr. Dennis Loh (Washington University, St. Louis).
0011.10 mice from Dr. Loh's laboratory were maintained on an H-2d background and
were routinely mated to BALB/c mice.
The male was placed into a specific pathogen free (SPF) room at Rockefeller
University's Laboratory Animal Research Center (LARC) and acclimatized for several
days. The original male was then mated to four new 8-9 week old BALB/cBy females
every week. The females were also kept under SPF conditions and acclimatized for at
least a week after arrival at LARC. As soon as they were visibly pregnant, the females
were placed into separate cages. Pups from these mice were weaned at 3-4 weeks of age.
At the time of weaning, ear markings were made on the left and/or right ear(s) of the
mice with an ear punch (National Band & Tag Co., Newport, KY). Thus each individual
mouse could be identified by sex, cage card number, coat color (approximately 50% of
the pups were white the other 50% agouti), and ear markings.
Since the male was heterozygous for both transgenes, only 50% of its offspring would
be TCR transgenic (the two transgenes were injected as a linear construct and therefore
always cosegregate). The pups therefore had to be screened for the presence of the
transgenes. For screening, genomic DNA was obtained from the tail tips of mice and the
polymerase chain reaction (PCR) performed on the DNA using probes specific for the a
transgene (since the two transgenes always cosegregate, mice transgenic for the a chain
would also be transgenic for the f3 chain).
Tail tips were taken during weaning, right after the ear markings were made.
Approximately 2cm of the tail tip was cut off with scissors, cut into 2 pieces and then
placed into an autoclaved 1.5 ml tube containing 0.5 ml of proteinase K buffer. Scissors
and forceps were wiped with ethanol pads between mice to prevent cross contamination.
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Proteinase K buffer:
0.1 M NaCI
0.01 M EDTA pH 8.0
0.05M Tris pH 7.5
1% SDS
0.3 mg/ml Proteinase K
(1 ml of 5 M stock/50ml)
(1 ml of 0.5M/50ml)
(2.5ml of 1 M/50ml)
(2ml of 25%/50ml), premixed then add
(15mg/50ml ie. 0.75 ml of stock)
Proteinase K (Boehringer Mannheim, Indianapolis, IN) was resuspended at a
concentration of 20 mg/ml in sterile ddH20. Aliquots were stored at -20C.
Tail tips were incubated in this buffer for 5-6 hrs at 50-55 C in a heating block. 0.5
ml of a 1:1 mixture of Tris equilibrated phenol (United States Biochemical, Cleveland,
OH) and chloroform was then added to each tube. A new pipette tip was used for each tube
to prevent cross contamination. The tubes were vortexed vigorously and then centrifuged
at 11,000 x g for 10 minutes in a microcentrifuge. 0.45 ml of the supernatant was
removed and placed into a tube containing 0.5 ml of chloroform. The tubes were vortexed
again and centrifuged for 5 minutes at the same speed. 0.4 ml of supernatant was
removed and placed into tubes containing 0.8 ml of ice cold absolute ethanol. The DNA was
precipitated at -70C for at least 6 hrs but usually overnight. The tubes were then
centrifuged for 30 minutes at 11,000 x g at 4 C. The pellets were washed once with ice
cold 70% ethanol, centifuged for 5 minutes, and then air dried under a hood. The dried
pellets were resuspended in 50 ul of TE and kept at -4 C (DNA samples). This DNA was
diluted at 1:10 in sterile ddH20 and used as the template for the PCR.
The sequences of oligonucleotides used for the PCR screens were obtained from the Loh
lab:
Va13 5' CAG GAG GGA TCC AGT GeC AGC 3'
Jo 5' TGG CTC TAC AGT GAG TIT GGT 3'
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These oligonucleotides were synthesized by Oligos etc. Inc. (New Haven, CT),
resuspended in sterile H20 at a concentration of 1 mM, and kept at -20 C. DNTPs,
mineral oil, magnesium stock solution, 10X PCR buffer, and Taq polymerase were all
purchased from Perkin Elmer (Norwalk, CT). PCR was carried out in 50 ul reactions in
0.5 ml tubes.
5.0ul 10x PCR buffer
4.0ul of 25mM Mg (2mM)
1.0ul of 10mM dATP (200uM)
1.0ul of 10mM dCTP (200uM)
1.0ul of 10mM dGTP (200uM)
1.0ul of 10mM dTTP (200uM)
0.25ul of 5U/ul Taq polymerase (1.25 U)
0.125ul of 1 mM Va. oligo (2.5uM)
0.125ul of 1 mM Ja. oligo (2.5uM)
36.5ul of ddH20. premix, add 2 drops of mineral oil then add:
1.0ul DNA (1:1 0 dilution of DNA sample)
The reaction was carried out in a Coy thermocycler using the following conditions:
5 min at 94 C (to denature template DNA)
(1 min at 94 C, 1 min at 55 C, 1 min at 72) = 1 cycle. Repeated 30 times.
10 min at 72 (to allow completion of DNA products)
The reactions were then kept at 4 C until a gel coud be run. Products were analysed by
agarose gel electrophoresis and staining with ethidium bromide. To analyze the products.
25ul of each reaction was mixed with 5 ul of 6X loading buffer and run on a gel.
2% agarose (Seakem, FMC Bioproducts, Rockland, ME) gels were made in 1X TAE buffer.
1 ul/1 00 ml of a 10mg/ml ethidium bromide solution (Sigma, St Louis, MO) was added
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to the gel and to the 1 X TAE running buffer. A 100 base pair DNA ladder (Gibco BRL,
Gaithersburg, MD) was used as the molecular weight standard. The PCR product was 300
base pairs long and was visualised with U.V. light. When results were equivocal, PCR was
repeated with DNA stock solutions diluted at 1:5 as well as to 1:10. All standard stock
solutions were made as described in Maniatis.
Nontransgenic mice: Thymectomized BALB/c mice were purchased from Taconic Farms.
Priming mice:
For footpad injections the antigen was first emulsified in complete Freunds adjuvant
(CFA, Sigma, St. Louis, MO). 1 ml Hamilton Gastight series teflon fluorocarbon resin
luer lock glass syringes (Reno,NV) were used for this process. An equal volume of CFA
and the antigen (up to 0.5 ml of each) were taken up into two syringes. The syringes
were connected with a three way stopcock (Sherwood Medical, St. Louis MO). The CFA and
antigen were then subjected to 100 - 200 cycles through both syringes where 1 cycle
represents the complete passage of the suspension from syringe 1 to syringe 2 and then
back to syringe 1. Injections were done with these same syringes fitted with 25 gauge
needles. The mice were first anesthetized with Nembutal (pentobarbital sodium
injection, Abbott laboratories, North Chicago, IL). A 50 mg/ml stock solution was
diluted 1:10 with Hanks Balanced Salt Solution (HBSS, Gibco) and 0.3 ml (medium sized
mice) or 0.4 ml (larger mice) of this dilution was injected into the peritoneum of mice
with a 25 gauge needle. A total of 200 ul of the suspension was injected over all four
footpads of each mouse. SEB was purchased from Toxin Technology (Sarasota, FL),
resuspended at 1 mg/ml in RPMI1640 medium, aliquoted, and stored at -70 C. If 50 ug
of the toxin was to be injected into each mouse, the SEB solution was diluted 1:1 with
PBS or HBSS . The concentration would now be O.5mg/ml or 50 ug in 100 ul. This
solution was then mixed 1:1 with CFA resulting in a final concentration of 0.25mg/ml or
50 ug in 200 ul.
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For intravenous injections, mice were placed in cages without bedding and these cages
were then placed onto an electric heating pad (purchased from a local drugstore) for
10-15 minutes. The mice were then suspended through the cage cover racks by their
tails and 0.1 ml of antigen was injected into their dilated lateral tail veins with a 25
gauge needle.
Mice were sacrificed with C02 usually 10 days after priming. The scissors and forceps
used in the dissections and the fur of the mice were first disinfected with 70%
isopropanol. Spleens and/or lymph nodes (LN) were taken and placed into a tube
containing sterile HBSS. For footpad injections, the axillary, brachial, popliteal and
inguinal LNs were harvested and pooled. To extract cells from spleens and LNs, the
plunger of a 1 ml syringe was used to force the organs through a 40 or 60 mesh screen
held in a "Cellector" tissue sieve (Electrochemical Apparatus, St. Petersburg, FL). Each
screen was then washed with 12 ml of HBSS and then the cell suspension [collected in a
sterile standard10 x15mm petri dish, (Fisher Scientific)] was centrifuged at 1600,
RPM at 4 C for eight minutes. Red blood cells were removed by resuspending the cells
into a 1:1 mixture of RPMI 1640 and a 1.66% solution of ammoniun chloride in sterile
ddH20. The cells were incubated in 12 ml of this solution (first prewarmed to 37 C )
for 3-4 minutes and were then centrifuged again. The cells were then resuspended in
HBSS and centrifuged (Le. washed) twice. Cells were counted in a 10% solution of
trypan blue (Gibco) in HBSS with a hemocytometer.
Proliferation assay.
Peptide. OVA 323-339 (ISQAVHAAHAEINEAGR; M.W. 1774) was synthesized and
purified by the American Peptide Company (Sunnyvale, CA). The peptide was> 97%
pure as determined by HPLC. The lyophilized peptide was stored at -20 C. For each
assay a small amount ( -0.5 mg ) would be weighed out on an analytical balance and a
1 mM stock solution of was made in RPMI 1640. Ovalbumin (grade V) was purchased
from Sigma and kept at 4 C. For each assay a 10 mg/ml stock solution was made. SEB was
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purchased from Toxin Technology (Sarasota FL), resuspended at 1 mg/ml, aliquoted and
stored at -70 C. Con A (Boehringer Mannheim) was resuspended at 5 mg/ml and was
kept at 4 C.
PMA was purchased fom Sigma, resuspended at 1 mg Iml in DMSO (Sigma), aliquoted and
stored at -20 C. lonomycin (Calbiochem, San Diego, CA) was resuspended at 10 mg Iml
in DMSO, aliquoted, and stored at -20 C.
For the assay cells were resuspended at 106 cells/ml in "R+D" culture medium [a 1:1
mixture of RPMI 1640 +DMEM high glucose (Gibco) supplemented with 10% FCS
(Hyclone, Logan, UT), 1 mM glutamine, SOuM 2-ME, penicillin, streptomycin and
amphotericin B (purchased as antibiotic-antimycotic solution, Gibco)] and 200 ul (2 X
105 cells) per well dispensed into 96 well flat bottom Corning plates (Fisher). The
cells were stimulated with various concentrations of SEB, or OVA 323-339, or with
either 100 ug/ml ovalbumin, or 2.5 ug/ml Con A. For receptor cross linking studies,
KJ1-26 (2.5 or Sug/ml in HBSS) or anti CD3 mAb (2 ug/ml; clone145-2C11,
PharMingen, San Diego CA) was immobilized onto 96 well plates (100 ul/well) by
incubating overnight at 4· C. The plates were washed three times with HBSS before use.
LN CD4+ cells were obtained by passing lymph node cells over CD4 purification
columns as per the manufacturer's instructions (Biotex, Edmonton, Canada). The cells
were 90-95% CD4+ as determined by FACS analysis. BALB/c spleen cells were cultured
at 2 x 106 cells/ml in RPMI 1640 medium (supplemented as described above) with 15
ug/ml of LPS (S. Minnesota R595, List Biologicals, Campbell CA) for 3 days. The cells
were then inactivated with irradiation (3000R) from a 137Cs source, washed twice and
used as antigen presenting cells. 5 X 104 CD4 cells + 5 X 104 irradiated LPS blasts per
well were cultured in the presence of different stimuli as described above.
Splenic CD4+ cells were obtained by treating the cells with anti CDB mAb. Culture
supernatant from the 3.155 hybridoma (ATCC TIB 150) used at a final concentration of
1:5 was incubated with cells suspended in RPMI 1640 at a concentration of 107
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cells/ml on ice for one hour. The cells were pelleted by centrifugation at 1600 RPM
for8 minutes and then resuspended at 4 X 107/ml in a 1:10 solution of 4 week old baby
rabbit complement (Pel-Freez, Rogers, AR) .The cells were incubated at 37 C for 45
minutes and were then washed two times with RPMI 1640 medium. Cells at this stage
were used as "CD8 T cell depleted spleen cells". If purified CD4 cells were needed, the
cells were then subjected to panning. Standard10 X 15mm petri dishes, (Fisher) were
coated with 5 ml of goat anti mouse anti IgG and IgM antibody (Jackson ImmunoResearch,
West Grove PA) in 50 mM Tris pH 7.5 at a final concentration of 20 ug/ml for I hr at
room temperature. The plates were then washed four times with HBSS. 5 ml of RPMI
with 5% FCS was added and the plates were stored at 4 C until they were ready to be
used. A maximum of 108 cells in 4.5 ml of RPMI 1640 with 5% FCS was added to each
plate and the plates were then incubated at 4 C for an hour. The plates were then gently
agitated from side to side and non adherent cells harvested. The plates were then gently
washed two times with 5 ml of HBSS. The cells and the two washes were pooled and
centrifuged as described.
The cells were then passaged over nylon wool columns. Nylon wool (NW)
(Polysciences, Warrington PA) was first untangled with dog brushes or combs and then
squeezed into either 5 ml (0.5 gm NW), 10 ml (1 gm NW) or 20 ml (2 gm NW)
syringes (Becton Dickinson) and autoclaved. 3 X 108 bulk spleen cells/gm NW were
used. After the colums were washed with RPMI, the plungers were removed and three
way stopcocks (Sherwood Medical) were attached to the syringes. RPMI containing 10%
FCS, was run through the column and the column was then incubated at 37 C for one
hour. The cells were then added in an amount of medium that was just sufficient to enter
the column. Another 1 ml of mediun was added and after an hour incubation at 37 C , the
cells were eluted at a rate of one drop every 2 seconds. After this step the cells were at
least 85% CD4+ as determined by FACS analysis.
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These cells were used with A20 cells, an H-2d B cell lymphoma line from ATCC,
(Rockville, MD) or TA3 cells an H-2d,k B cell lymphoma line, or its B7 transfected
derivative TA3-mB7 (93). A20 cells were inactivated with 17,000R, TA3 cells were
inactivated with 20,000R. 5 X104 CD4 cells were incubated with 104 lymphoma cells
in the presence of different stimuli as described in the Results section. Purified anti­
CD28 mAb was purchased from PharMingen.
After either 48 or 68 hrs, 1 uCi of 3H thymidine (Amersham, Arlington Heights, IL)
in 15 ul of media was added to each well and the cells were harvested 14 -18 hrs later
onto glass fiber filter mats (Pharmacia LKB, Gaithersburg MD) with an automatic
harvester (Skatron Inc, Sterling, VA). The filters were dried for an hour in a 37 Coven,
placed into a special sample bag (Pharmacia LKB) with scintillation cocktail (Beckman,
Fullerton CA) and were then counted with a Betaplate counter (Pharmacia LKB).
Triplicates were run for each sample and the mean determined. In some experiments,
after 48 hrs, the cells were removed from wells and centrifuged at 1600 RPM at 4 C for
5 mins to harvest the culture supernatant which would then be used in IL-2 assays. The
cells were then resuspended in complete medium, redispensed into their original wells,
and then pulsed with 3H thymidine.
IL-2 secretion assay.
Cell lines: HT- 2 cells were a gift from Dr. Y. Choi (The Rockefeller University, New
York, NY), CTLL-2 cells and concentrated anti interleukin 4 supernatant (clone 11 B11,
ammonium sulfate precipitate) were from Dr. T. Rao and Len Appleman (NYU School of
Medicine). Recombinant mouse IL-2 (Collaborative Research, Belford, MA) and
recombinant human IL-2 (Promega, Madison WI), were resuspended at 10,000 units
Iml (10 UI ul), aliquoted, and stored at -70 C.
LN cells at 106 cellslml or 5 X105 CD4 cells + 5 X104 irradiated (6000R) A20
cells Iml were cultured in R+D medium in the presence of a given mitogen. The cells
were cultured in either 24 well flat bottom plates at 1 ml per well, or in 96 well flat
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bottom plates at 200 ul per well (proliferation assays). After 48 hrs, the culture
supernatants were harvested, reconstituted with medium to the original volume, and
kept at - 70 C until use.
CTLL-2 cells were grown in RPMI1640 supplemented with 10% heat inactivated FCS
(from Len Appleman), nonessential amino acids, sodium pyruvate, 1 mM glutamine,
penicillin, and streptomycin (all from Gibco) and 20 Ulml of recombinant human IL-2 .
Gentamicin, amphotericin S, and 2-ME were not added as they were toxic to the cells.
The cells were passaged twice a week by resuspending 106 cells in 20 ml of medium.
Cells were used for the assay 3-4 days after they were passaged. They were washed once
and then IL-2 "starved" by incubation in medium without IL-2 for 4 hrs before the
assay. Cells were resuspended at 6.67 X 104 Iml in culture medium, and neutralizing
anti IL-4 mAb (1.5 ullml) was added. 75 ul (5 X103 cells) per well was then dispensed
into 96 well flat bottom plates. 4 - 8 serial twofold dilutions of the culture supernatants
to be tested were made and 25 ul of the dilutions was added to the cells. 8 -10 serial
twofold dilutions of recombinant mouse IL-2 (starting from 1 unit in 25 ul) were also
made and added to cells. The cells were pulsed with 1 uci of 3 H thymidine in 10 ul of
medium after 24 hrs in culture, and were harvested 16 - 20 hrs later as described for
the proliferation assay. Triplicates were run for each dilution of each sample and the
mean determined.
HT-2 cells were the gift of Dr. Y. Choi ( The Rockefeller University), and were
maintained and passaged by his laboratory. The cells were used in assays 2 days after
they had been passaged. The cells were resuspended at 2 X 105 Iml with 5 uglml of anti
I L4 in 50% modified complete tumor medium (CTM)I 50% Mishell- Dutton complete
cocktail. This mixture consists of a 3:2:1 ratio of modified CTM : nutrient cocktail (NC) :
FCS. Modified CTM is OMEM high glucose with glutamine and sodium pyruvate (Gibco)
supplemented with 10% FCS (Hyclone), 2 mM glutamine, 50 uM 2-ME, penicillin,
streptomicin, gentamicin, amphotericin S, and essential and non essential amino acids
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(added just before the assay, all reagents from Gibco). 50 ml of nutrient cocktail was
made from 35 ml of MEM medium (Gibco), 5ml of essential amino acids solution (SOX),
2.5 ml of non essential amin acids solution (100X) 2.6 ml of glutamine (29.2 mg/ml)
[all from Gibco] and 0.5 g of dextrose (Sigma). The pH of the solution was then adjusted
to 7.0 with 10 N NaOH and 0.57 g of sodium bicarbonate (Sigma), and 5 ml of ddH20
added. The cocktail was then sterilized by filtration, divided into 2 ml aliquots (which
were used only once) and stored at -20 C.
20 ul (4 X103 cells) was dispensed into each well of 96 well flat bottom plates and 80
ul of culture supernatant or recombinant mouse IL-2 dilutions (made as described
above) was added to the cells. 1 uci of 3H thymidine in 10 ul of medium was added to each
well after 18 hrs of culture and the cells were harvested 12 hrs later. For each assay, a
standard curve was generated using X (concentration), and Y (thymidine incorporation;
CPM) values from the recombinant IL-2 dilutions. These values were then plotted on a
Cricket Graph (Computer Associates, Islandia, NY). Those points that fell into a roughly
straight line were taken and the equation,
Y = mX + b or
where m and b were determined by the program.
m
was used to determine the concentration of IL-2 present in the culture supernatants
Calcium flux assay: 50 ug aliquots of lyophilized Indo 1-AM were purchased from
Molecular Probes (Eugene OR) and stored at - 20 C. Just before each assay one aliquot
was reconstituted in 50 ul of DMSO (Sigma). Indo-1 loading buffer (Gibco) contained
5.36 mM KCI, 0.44 mM KH2P04, 136.87 mM NaCI, 4.16 mM NaHC03, 0.3357 mM
Na2HP04·7H20 11.101 mM Glucose, 5.0 mM HEPES 2.0mM CaCI2'2H20, 0.1% BSA,
pH = 7.3. LN cells were suspended at 5 X 106 cells I ml in 'the loading buffer and loaded
with 4 ug Iml of Indo 1-AM for 1 hr at 37 C. Cells were washed twice and resuspended at
106 cells Iml in loading buffer. The cells were incubated at 37 C for 2 mins before each
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experiment. Fluorescence was measured in a spectrofluorimeter (SPF -SOOC, SLM
Aminco Instruments Inc, Urbana, IL) with an excitation of 350 nM and emission
recorded at 510 nM. 2 X 106 cells were analyzed in spectrofluorimeter cuvettes (SLM
Aminco Instruments). After a steady baseline was obtained, the specified mitogen was
added. At the end of each experiment, the loaded Indo-1 was released by solubilizing the
cells with Triton X 100 (Sigma); 5 ul Iml of a 10% stock solution was added to obtain
the maximum fluoresence levels (F max). The calcium chelator EGTA was then added to a
final concentration of 5 mM to obtain the minimum fluorescence (F min). Intracellular
calcium concentration was determined by the equation:
(Ca2+}i = Kd (F - F min}1 (Fmax - F)
where Kd is the dissociation constant of Indo-1 for Ca2+ (250 nM) and F is the observed
fluorescence.
FACS analysis: Anti-CD4 PE (clone RM4-5), anti CDB PE (clone 53-6.7}anti CD44 PE
(clone IM7) anti V�8.1IB.2 FITC (clone MR5-2) anti Cl� TCR FITC and purified anti B�
were all purchased from Pharmingen. Biotinylated or purified KJ1-26 (obtained from
the Loh lab) was used with streptavidin FITC (Pharmingen) or FITC conjugated F(ab}2
goat anti mouse IgG (Fc specific Jackson ImmunoResearch, West Grove, PAl
respectively. Anti I-Ad (clone MKD6) and I-Ed (clone 14-44) were culture
supernatants from hybridomas purchased from ATCC and were used with FITC conjugated
F(ab)2 goat anti mouse IgG. Purified anti CD32 ("Fc block" clone 24G2, Pharmingen)
was used to decrease non specific staining. It was not used during staining with
unconjugated mAbs as it reacted with the secondary antibodies.
As a general rule, 1 ug of mAb in 100 ul of FACS buffer [1% bovine albumin, (Cohn
fraction V, pH 7.4, Sigma) in PBS] or 100 ul of culture supernatant was used to stain
106 cells. If 105 cells were to be stained, they would be centrifuged at 1600 RPM for 4
minutes at 4 C, and then resuspended in 10 ul of this mAb containing buffer. Cells were
usually stained in 5 ml Falcon 2058 tubes (Fisher) for 25 minutes at 4 C and then
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washed twice with FACS buffer (1 ml for the first wash, 0.5 ml for the second wash).
For secondary staining, FITC conjugated goat anti mouse IgG (Fc specific) or streptavidin
FITC was diluted at 1 : 100 in FACS buffer and 30 ul of this solution was added to 105
cells. The goat anti mouse IgG cross reacted slightly with many of the rat mAbs,
therefore if a 2 color analysis was to be performed with unconjugated KJ1-26 and CD4
PE and/or CDB PE, the cells would be first treated with KJ1-26, washed twice, stained
with FITC conjugated goat anti mouse IgG, washed twice, and then finally stained with the
PE conjugated rat monoclonal. The cells were resuspended in 300 ul of FACS buffer and
immediately analyzed on a FACScan (Becton Dickinson). In some instances, the cells
were fixed with 3.7% formaldehyde solution (37% stock solution (Fisher) diluted 1: 10
in FACs buffer was added to cells at the very last step). Fixed cells were wrapped in foil
and kept at 4 C for up to 3 days after staining.
104 events per sample were usually aquired. A dot blot of forward scatter versus side
scatter was obtained and non viable cells were gated out by size. Dot blots of FL1 (FITC)
vs FL2 (PE) were then obtained. Cells stained with only secondary reagents or with
isotype matched non specific mAbs were used as controls to determine background
staining. Duplicates were run for most samples, the mean determined, and background
fluorescence staining subtracted.
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Chapter 1.3 (Results)
Induction of tolerance in mature T cells by SEB
In order to confirm published results on the ability of SEB to tolerize mature V�8 T
cells, BALB/c mice were immunized intravenously with 50 ug of SEB per mouse. As
shown in Table I, a clonal expansion of V�8 T cells took place by day 3. This is consistent
with published reports. By day 10, the V�8 T cells were deleted to a level that was
slightly lower than that found in control mice (Table I). V� 6 cells are not SEB
responsive and were largely unaffected throughout the course of the experiment (Table
I). The remaining V�8 T cells appeared to be functionally tolerant in that they responded
poorly to SEB in vitro (Fig. 1 a). T cells from these mice could, however respond well to
the lectin Con A (Fig. 1 b) implying that the observed tolerance was specific for SEB.
In other experiments, SEB was emulsified in CFA and inoculated subcutaneously into
thymectomized BALB/c mice. Table" shows that there was a significant decrease in the
number of V�8 but not control V� 14 C04 T cells in the draining lymph nodes of these
mice. The remaining cells responded poorly to SEB (Fig. 2a) and to immobilized anti
V�8.1 + 8.2 mAb (Fig. 2c) but responded as well as control cells in response to
immobilized anti C03 mAb (Fig. 2b). This further confirms that the effect of SEB was
specific for a subpopulation of T cells (V�8 +).
a6 TCR transgenic mice
The next set of experiments were designed to follow the response of a monoclonal
population of primary T cells to the superantigen SEB, in mice transgenic for the a and
� TCR chains from the OVA specific hybridoma 0011.10. A 0011.10 transgenic mouse
and a non transgenic littermate were phenotyped as shown in figure 3. Virtually all
C04+ T cells in both the transgenic mouse and the non transgenic littermate were C03+.
The transgenic V�8.2 chain was expressed by virtually all T cells in the transgenic
mouse. In contrast only 13% of C04 cells in non transgenic mice expressed endogenous
V �8.2 as part of their T cell receptor. The clonotypic mAb KJ1-26 detects the
combination of the 0011.10 TCR a and � chains. It follows that only those T cells in
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Table I. Percentage of V�6 and V�8 CD4+ T cells in control and day 3 SEB primed mice.
Y.1iQ._ YllB.
Control mice
SEB primed mice
9.5%
7.2%
23.1%
47.5%
Percentage of V�6 and V�8 CD4+ T cells in control and day 10 SEB primed mice.
Y!i£_ YllB.
Control mice
SEB primed mice
12.2%
12.2%
26.1%
22.0%
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Table II. SEB + CFA immunizations
Percentage of V�14 and V�8 CD4+ T cells in control and SEB primed mice (day 10).
V614 V68.1+8.2 Yaa
Control mice
SEB primed mice
10.0%
11.1%
29.0%
12.2%
19.6%
8.1%
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Figure 1. Proliferation of spleen cells from either PBS (open circles) or SEB (closed
triangles) primed mice in response to either SEB (a) or 2.5 ug/ml of Con A (b). Cells
were pulsed with 3H thymidine on day 3 and harvested on day 4. The mean of
triplicates is shown for all experiments.
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Figure 2. Proliferation of purified CD4 cells from either PBS (open circles) or SEB
(closed triangles) primed mice in response to either SEB (top) or 2 ug/ml of anti CD3
(bottom left) or 5 ug/ml of anti V�8.1 +8.2 (bottom right). Cells were pulsed with 3H
thymidine on day 3 and harvested on day 4.
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transgenic mice that express both TCR transgenes will react with this mAb; the
remaining T cells will be cells that express the transgenic � chain in combination with
endogenous a chains. As expected virtually none of the cells in the non transgenic mouse
reacted with this mAb whereas 45% of all C04 cells in the transgenic were KJ1-26+.
Figure 4 shows that the proliferative responses of T cells from the above mice
correlated well with their phenotypes. Cells from the transgenic mouse but not from the
non transgenic littermate proliferated in response to both native ovalbumin and to the
exact peptide epitope OVA 323-339. Cells from both mice responded to SEB, but cells
from the transgenic mouse showed an increased response presumably due to the
increased number of V�8 T cells. As a negative control, the proliferative response of
transgenic cells to the superantigen SEA was tested. This toxin reacts with T cells that
express V� segments other than V�8. Figure 4d shows that the nontransgenic T cells
responded much better to this superantigen than did transgenic T cells. We also looked at
the response to immobilized anti TCR mAbs. Cells from both mice responded well to anti
C03 (Fig. 5a) but only transgenic T cells proliferated in response to the clonotypic mAb
(Fig 5b).
I.V. injection of SEB into 0011.10 transgenic mice
Our main goal was to follow the response of a monoclonal population of primary T cells
to a superantigen. In initial experiments D011.10 mice were immunized intravenously
with 50 ug each of SEB. 2/6 SEB primed mice died over two experiments. Prior to this
no deaths had ever been seen in non transgenic mice treated with identical doses of SEB.
The toxic effect is therefore probably due to systemic release of cytokines such as TNF
by the transgenic T cells.
Ten days after injection, a significant decrease in the percentage of C04+ V�8+ T cells
was seen in SEB primed mice (17.5% in SEB primed mice compared to 32.2% in
controls; Fig 6). The ratio of C04/C08 V�8 T cells was also much lower in SEB primed
mice than in controls (Table III). In contrast the percentage of C04+ KJ1-26+ T cells
was only slightly decreased (11.3% in SEB primed mice vs. 13.7% in controls; Fig 6).
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Table III. CD4/CD8 ratio of V�8+ and KJ1-26+ T cells in control and SEB primed mice
Control mice
SEB primed mice
CD4/CD8: V68+
6.9
2.1
CD4/CD8: KJ1-26+
10.3
4.2
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Figure 4. Proliferation of spleen cells from either a transgenic (Tg) mouse (open
circles) or a non transgenic littermate (closed triangles) in response to either native
ovalbumin (a), OVA 323-339 (b), SEB (c), or 1 ug/ml of SEA (d). Cells were pulsed
with 3H thymidine on day 3 and harvested on day 4.
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Figure 6 FACS analysis of spleen cells from 0011.10 mice injected intravenously with
either PBS (a-c) or SEB (d-f) 10 days earlier.
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There was, however, a significant decrease in the ratio of CD4/CD8 KJl-26+ T cells in
SEB primed mice (Table III), implying either a selective deletion of CD4+ cells or a
selective expansion of CD8+ T cells. The number of CD4-CD8- T cells in SEB primed
mice was not significantly increased (Fig 6).
Surprisingly, despite the marked decrease in the number of V�8 T cells, cells from
SEB primed D011.10 mice proliferated as well as control cells in response to both SEB
and to OVA 323-339 (Fig. 7). The cells from SEB primed mice however secreted
significantly less interleukin 2 (IL-2) in response to SEB, OVA 323-339, and anti
CD3 mAb as determined by the decreased proliferation of the IL-2 dependent HT-2 cell
line. (Fig. 8).
Subcutaneous injection of SEB and CFA into D011.1 0 mice
Because of the high mortality seen in 0011.10 mice primed intravenously with SEB,
an alternative route of administration, footpad injections with SEB and CFA was used. In
contrast to the results seen with intravenous administration, the percentage of V�8.2+
and KJ-126+ lymph node (LN) T cells was only slightly reduced in mice primed
subcutaneously with SEB compared to controls (Fig.9). There was also no significant
increase in the numbers of CD4-CD8- T cells. In addition, downregulation of CD4, V�8,
or of the clonotypic receptor was not seen (Fig. 10 and Table IV).
Despite having comparable numbers of KJ-126+ cells, LN cells from SEB primed
mice proliferated poorly in response to either SEB or OVA 323-339 (Fig 11. a,b).
Reduced proliferation was also seen in response to the lectin Con A and to immobilized
anti-CD3 and KJl-26 mAb (Fig. 12). Purified CD4 cells from tolerized mice had a
somewhat improved proliferative response to SEB, to OVA 323-339, and to anti CD3
mAb compared with whole LN cells (Fig. 11,12), but they produced signicantly less IL-
2 in response to these stimuli than did control CD4 cells (Table V).
In contrast to this unresponsiveness to specific mitogenic stimuli, C04 cells from
tolerized animals were capable of proliferating in response to PMA and ionomycin {Fig.
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Table IV.
Mean channel fluorescence of CD4, V�8 and KJ1-26 on LN T cells from mice primed with
either CFA + PBS or CFA + SEB.
Treatment Qf mice
CFA + PBS CFA + SEB
CD4 expression on KJ1-26 cells
CD4 expression on V�8 cells
KJ1-26 expression on CD4 cells
V�8 expression on CD4 cells
347
339
81
68
322
295
72
67
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Figure 7 Proliferation of spleen cells from either PBS (open circles) or SEB (closed
triangles) primed D011.10 mice in response to either SEB (a) or OVA 323-339 (b).
Cells were pulsed with 3H thymidine on day 3 and harvested on day 4.
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Figure 8 Proliferation of HT-2 cells in response to culture supernatant from spleen
cells from either PBS (open circles) or SEB (closed triangles) primed 0011.10 mice
that had been stimulated with either 10 ug/ml of SEB, 100 nM of OVA 323-339, or 2
ug/ml of anti CD3. Some cells were grown with different concentrations ofrecombinant
mouse I L-2 and a standard curve generated. Cells were pulsed with 3H thymidine after
18 hrs and harvested 12 hrs later.
48
 
a b c
e.T.,,;
I
V�8-FITC KJ 1-26-FITC V�8-FITC
d e f
w- 33.�/.
c,
I
co
C
o
+
'lilt
1.4)!C
o
V�8-FITC KJ 1-26-FITC V�8-FITC
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Figure 10 Surface markers on T cells from control (panels A-D) or SEB primed
D011.10 mice (panels E - H). Cells were double stained with CD4 and V�8 or CD4 and
KJ1-26. Histograms show the expression of the specified antigen on double positive
cells.
A,E CD4 expression on KJ1-26+ cells
B,F KJ1-26 expression on CD4+ cells
C,G CD4 expression on V�8+ T cells
D,H V�8 expression on CD4+ T cells
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Figure 11 Proliferation of LN T cells (a,b) or purified CD4+ cells (c,d) in response
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Figure 12 Proliferative response of whole lymph node (WLN) or CD4 cells from
either PBS (control) or SEB primed mice to a, CD3 (2 ug/ml) b, KJ1-26 (2.5
ug/ml) c, Can A (2.5 ug/ml) or d, PMA (10 ng/ml) + ionomycin (200 ng/ml). Cells
stimulated with Mab were pulsed on day 2 and harvested14 hrs later. Cells from other
experiments were pulsed on day 3 and harvested on day 4.
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12d), suggesting that a proximal signal transduction step was affected in anergic cells.
In order to determine whether calcium mobilization was the defective step, we compared
the response of control and anergic cells to Con A. In marked contrast to their inability
to proliferate to this mitogen, LN cells from SEB primed mice could mobilize calcium as
well as control cells (Fig. 13). To determine whether the defect was due to decreased
PKC production, we stimulated the cells with SEB or with OVA 323-339 in the presence
of PMA. As shown in Figure 14, PMA was unable to reverse anergy to either antigen.
In order to determine whether the apparent tolerance could be due to suppression of
responsiveness by a cell subpopulation in SEB primed mice, LN cells from SEB primed
mice were cocultured with control LN cells. The presence of tolerant cells in coculture
did not affect the response of control cells to either SEB or OVA 323-339 (Figure 15).
Subcutaneous injection of OVA 323-339 and CFA into 0011.10 mice
To determine whether this tolerance was the normal outcome of an immune response,
0011.10 mice were primed with 50 ug of OVA 322-339 or with either 25 or 50ug of
SEB. As shown in Figure 16, there were no major differences in the percentage of V�8+
or KJ 1-26+ cells in any of these groups.
As the homing receptor C044 is thought to be upregulated on memory T cells (92),
we looked at the expression of this molecule on V�8+ and KJ1-26+ cells. C044
expression was markedly increased on KJ1-26+ LN cells from OVA primed mice (Fig
17A and Table V). In contrast there was only a moderate increase in C044 expression on
KJ 1 -26+ cells from mice primed with 50 ug of SEB (Fig 178 and Table VI). The
expression of C044 on the entire V�8 population was only slightly increased in LN cells
from mice treated with SEB, and remained unchanged in OVA primed mice (Fig. 17 C,O
and Table VI).
Cells from mice primed with OVA proliferated normally (Fig 18a) and secreted
significant levels of IL-2 (Table VII) in response to SEB. In contrast their proliferative
response to OVA 323-339 was greatly increased (Fig 18b). A dose response effect of
SEB is seen in the proliferative response to both SEB and OVA 323-339.
53
 
Table V. IL-2 secretion (U/ml) in response to various stimuli by purified CD4 cells
from SEB primed and PBS primed (control) D011.10 mice.
Control
SEB primed
SEB (10 ug/ml)
67.8
3.3
OVA 323-339 (100 nm)
23.6
4.4
54
anti CD3 (2 ug/ml)
6.81
0.73
 
Table VI. Mean channel fluorescence of CD44 on V�8 and KJ126 LN T cells from mice
primed with either CFA + PBS (control), CFA + 50 ug of OVA 323-339 (OVA) or CFA +
50 ug of SEB (SEB)
Control
CD44 expression on V�8 cells 139
CD44 expression on KJ1-26 cells 168
OVA
137
275
SEB
181
235
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Table VII. IL-2 secretion (U/ml) in response to various stimuli by LN cells from
D011.10 mice primed with either CFA only (control), 25 ug SEB (SEB 25), 50 ug SEB
(SEB 50), or 50 ug OVA 323-339 (OVA).
Treatment of LN cells
Treatment Qf SEB (1 Q UQLml) QVA 323-339 (1 QQ nm) anti QD3 (2 ug/ml)
�
CFA only 110 11.4 6.7
SEB 25 2.4 1.0 <0.4
SEB 50 3.5 0.9 <0.4
OVA 50 23.2 2.9
56
Figure 13 Calcium flux assay. Indo 1 loaded control (a) or anergic (b) cells were
stimulated with 10 ug/ml of Con A. The break in the graph represents the point of Con
A addition. The numbers are [Ca2+]i concentration at the indicated points.
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Figure 14 Proliferative response of lymph node (LN) cells from either PBS (control)
or SEB primed mice to 1 ug/ml of SEB or 100nM of OVA 323-339 in the presence or
absence of 10 ng/ml of PMA. Cells were pulsed on day 3 and harvested on day 4.
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Figure 15 Coculture of LN T cells from control and SEB primed mice. Control cells
(filled bar) or control cells + anergic cells (open bar) were cultured in the presence
of 100 nM OVA 323-339 (a) or 1 ug/ml of SEB (b). 2 X105 cells from each group
were cocultured. Cells were pulsed on day 3 and harvested on day 4.
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Figure 16 FACS analysis of LN cells from 0011.10 mice primed with either CFA +
PBS (A,B) CFA + 50 ug of OVA 323-339 (C,O), CFA + 50 ug of SEB (E,F) or CFA +
25 ug of SEB (G,H)
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Figure 17 Expression of CD44 on D011.10 LN T cells. Cells were double stained with
either CD44 and KJ1-26 or CD44 and V�8. KJ1-26+ (A,B) or V�8+ (C,D) cells were
gated on and their levels of CD44 displayed as histograms. Overlays are shown of
histograms from cells from CFA + PBS primed mice (PBS) vs. cells from either CFA +
50 ug SEB (SEB) or CFA + OVA 323-339 (OVA) primed mice.
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Figure 18 Proliferative response of cells from D011.10 mice primed with either CFA
+ PBS (Control), CFA + 25 ug of SEB (SEB-25), CFA + 50 ug of SEB (SEB-50), or
CFA + 50 ug of OVA 323-339 (OVA) in response to either SEB (a) or OVA 323-339
(b). Cells were pulsed after 48 hrs and harvested 14 hrs later.
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Cells from mice treated with �5 ug of the superantigen responded better than mice
treated with 50ug (Fig 18a,b). However cells from both sets of mice secreted very low
levels of IL-2 in response to either of the two antigens (Table VII). Similar results
were obtained in three separate experiments as shown in Table VIII.
Addition of exogenous IL-2
Since IL-2 secretion was markedly reduced in anergic cells, and since IL-2 is
necessary for T cell proliferation, the effect of adding exogenous IL-2 on anergy was
tested. Mice were primed with either 25ug or 50 ug of SEB. No deletion of V�8 or KJ1-
26 cells (Fig. 19) was seen. In contrast to earlier experiment, there was no difference
in the proliferative response of cells from mice treated with 25 ug of SEB and those
treated with 50 ug of SEB (Fig. 20 a,b, Fig. 21 a). 100 U/ml of IL-2 did not reverse
anergy to either SEB (Fig. 20a), OVA 323-339 (Fig 20b), or to immobilized anti TCR
mAbs (Fig. 21 b).
64
 
Table VIII. Proliferative responses of lymph node cells from 0011.10 mice primed with
either 25 ug SEB (SEB 25), 50 ug SEB (SEB 50), or 50 ug OVA 323-339 (OVA).
Stimuli are 1 ug/ml of SEB, 50 nM of OVA 323-339, 2 ug/ml of immobilized anti C03
or 5 ug/ml of KJ126 mAb, 100 ug/ml of ovalbumin. Results are shown as % of the
proliferative response of cells from 0011.10 mice primed with CFA only as a control.
Thymidine incorporation was measured as described in Materials and Methods. NO: not
determined.
Treatment of mice SfJL QY.A_ qCD3 KJ1-26 Ovalbumin
Expt.1 SEB 50 20.9% 14.3% 33.9% 26.2% NO
OVA 89.6% 137% 122% 127% NO
Expt.2 SEB 50 48.5% 33.4% 37.7% 34.4% 38.6%
OVA 112% 310% 79.2% 122% 350%
Expt.3 SEB 50 22.9% 0% 3.2% ND 9.1 %
SEB 25 69.1% 31% 8.7% NO NO
OVA 143% 470% 64.3% NO 189%
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Figure 19 FACS analysis of LN cells from 0011.10 mice primed with either CFA +
PBS (a,d), CFA + 50 ug of SEB (b,e), or CFA + 25 ug of SEB (c,f).
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Figure 20 Proliferative response of cells from mice primed with either CFA + PBS
(PBS), CFA + 25 ug of SEB (S-25), or CFA + 50 ug of SEB (S-50) in response to
either SEB (a) or OVA 323-339 (b). In c and d 100 Ulml of recombinant mouse IL-2
was added to each dose of mitogen. This dose of IL-2 had very little effect on control
cells (not shown). Cells were pulsed after 48 hrs and harvested 14 hrs later.
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Figure 21 Proliferative response of cells from mice primed with either CFA + PBS
(PBS), CFA + 25 ug of SEB (S-25), or CFA + 50 ug of SEB (S-50) in response to
either native ovalbumin (a) or to immobilized anti CD3 or KJ1-26 in the presence or
absence of 100 U/ml of recombinant mouse IL-2 (b). Cells treated with mAb were
pulsed after 48 hrs and harvested 14 hrs later, Cells stimulated with native
ovalbumin were pulsed on day 3 and harvested on day 4.
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Chapter 1.4 (Discussion)
Superantigens stimulate T cells primarily through the V� element of the T cell
receptor (TCR). The development of mAbs to different V� elements has enabled
investigators to physically identify superantigen reactive T cells, with major
implications for the study of tolerance.
White et at, first showed that treating neonatal mice with the superantigen SEB
resulted in the selective deletion of immature thymocytes expressing SEB reactive
receptors (58). This work was followed up by studies showing that peripheral T cells
in adult mice could also be tolerized by SEB (70,71). Inoculating mice with SEB
results in clonal expansion followed by partial deletion of V�8+ T cells (72,73). The
remaining cells were hyporesponsive to SEB (70,71), and to anti V�8 mAbs (71) and
as such were termed anergic. However, recent studies have shown conclusively that
other TCR elements may influence the reactivity of V�8 to SEB. Using a panel of
hybridomas derived from V�8 TCR transgenic mice, Smith et at. demonstrated that
individual V�8+ T cells vary greatly in their ability to respond to SEB (6). Since
these hybridomas express identical � chains and respond comparably to anti TCR mAbs,
it is clear that other TCR elements playa role in SEB recognition. A likely candidate is
the v« segment. In a recent study, SEB was used to induce clonal deletion in V�8.1
transgenic mice (89). When the remaining V�8 cells from these mice were compared
to V�8 cells from control transgenic mice, a marked skewing of the Va. repertoire was
seen (89).
In addition, in a recent study where V�8.2 TCR transgenic mice were tolerized with
SEB, it was shown that while the remaining T cells did not respond to SEB, they
proliferated as well as control cells in response to anti TCR mAbs (94).
Taken together, these studies suggest a possible alternative explanation to anergy,
namely that priming mice with SEB results in the selective deletion of highly reactive
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clones and that this selective deletion, rather than true clonal anergy, may account for
some of the diminished response to SEB.
We used aJ3 TCR transgenic mice to address this issue. T cells from these mice
express both TCR chains from the OVA specific hybridoma 0011.10, respond to OVA
323-339 in the context of I-Ad, and can be detected by the clonotypic mAb KJ1-26. In
addition the 13 chain is VJ38 and the cells are thus specific for the superantigen SEB as
well as for the conventional antigen OVA. We reasoned that KJ-126+ cells expressed
identical TCR elements and as such should all be equally responsive to SEB. Thus we
would be able to follow a monoclonal response to a superantigen and determine whether
true clonal anergy was occurring.
When 0011.10 mice were immunized intravenously with SEB, partial clonal
deletion of VJ38 and KJ1-26 C04 cells was observed. Surprisingly, the remaining cells
could proliferate as well as control cells in response to SEB and 'OVA 323-339. The
cells, however, secreted reduced levels of IL-2 in response to these stimuli suggesting
that they had been at least partially tolerized.
No major deletion of either VJ38+ or KJ1-26+ cells was seen when 0011.10
transgenic mice were primed subcutaneously with SEB emulsified in CFA, yet cells
from these mice were hyporesponsive to OVA 323-339 as well as to SEB, a finding
consistent with true clonal anergy. It is not clear why different results were obtained
with the different routes of inoculation. It is possible that different antigen presenting
cells were involved in the two systems leading to different outcomes. It is also possible
that the emulsification of SEB in CFA led to a slower release of the antigen and that this
difference in kinetics resulted in anergy and not deletion. The response of mice treated
intravenously with SEB is similar to that seen when VJ38.1 TCR transgenic mice are
tolerized with Mls-1 a spleen cells. T cells from these mice will proliferate but not
secrete IL-2 in response to Mis antigen present on activated B cells (101).
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While T cells from mice primed subcutaneously with SEB appeared to be anergic, we
cannot completely rule out selective deletion as being responsible for some of the
observed tolerance to SEB, as not all V�8.2+ T cells express the transgenic ex chain
(these cells are KJ1-26-). It is thus possible that a small number of highly SEB
reactive V�8+ KJ1-26- T cells were deleted. While this might explain why the IL-2
response was more affected in response to SEB than to OVA, it would not explain the
diminished response to OVA under the same conditions. For this, clonal anergy would
appear to be the only explanation: only KJ1-26+ cells can respond to OVA and no
deletion of these cells was seen in mice primed with 25 ug of SEB. Another possible
explanation is downregulation of TCR and/or CD4 in SEB primed mice, leading to
anergy. However, no significant down regulation of either V�8, the clonotypic TCR, or
CD4 was seen in cells from SEB primed mice. Finally, active suppression is not likely
to be the cause of the observed tolerance as cells from SEB primed mice did not inhibit
the response of control cells to either SEB or to OVA 322-339.
This study confirms and extends recent work by Perkins et aI., in which V�8.2 TCR
transgenic mice were inoculated with SEB (95). T cells from these mice were non
responsive to different superantigens, mitogens, and anti CD3 mAbs. By using ex� TCR
transgenic mice, we have been able to follow a monoclonal response and have thus been
better able to rule out selective deletion of highly SEB reactive V�8 clones as a cause of
tolerance. Further supporting the interpretation that anergy occurred, we have shown
that IL-2 production as well as proliferation is affected in the anergic cells,
noteworthy because the inability to secrete IL-2 has been reported as the major defect
present in anergic T cell clones (96).
Defect in aneroic T cells
It is noteworthy that the cells were anergiC to both a conventional antigen and a
superantigen, as several studies have implied that the two sets of antigens are coupled
to different signalling pathways (97-100). If this is true, then our results would
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imply that the defect in anergic cells lies in a step common to both pathways. The
ability of PMA and ionomycin to stimulate anergic cells suggests that a proximal signal
transduction step is affected, but this step is not likely to be calcium mobilization as
anergic cells were able to mobilize calcium normally in response to Con A. Similar
results have been recently reported by Yui et at, in V�B.1 TCR transgenic mice
tolerized with spleen cells fom mice bearing the endogenous superantigen Mls-1. In
their system, T cells were able to mobilize calcium but not proliferate in response to
cross linking with anti TCR mAbs (101). In the same system, diminished tyrosine
phosphorylation of two unidentified protein substrates in response to anti-CD3
stimulation was demonstrated (102). The characterization of these proteins will
probably lead to a better understanding of the exact molecular defect present in
anergic primary T cells.
It is interesting that the addition of IL-2 did not reverse anergy in our system. This
would imply that decreased IL-2 secretion alone is not the cause of the poor
proliferative response of the cells to various antigens. This again suggests that a
proximal rather than a distal signal transduction step is affected. Similar results were
found by Perkins et at. when V�B.2 TCR transgenic mice were tolerized with SEB. In
another system, in which V�B.1 TCR transgenic mice were tolerized with Mls-1 a
spleen cells, it was found that IL-2 did not restore the proliferative response of CD4 T
cells to either Mls-1 a stimulator cells or to anti CD3 mAb (102). The response of
COB T cells to anti-CD3 COUld, however, be restored by the addition of exogenous IL-2
(102). In a more recent study where V� B.2 TCR transgenic mice were tolerized with
SEB, it was found that 30 U/ml of exogenous IL-2 would fully restore the
proliferative response to SEB (94). It is not clear why different results are seen in
different systems, but it is possible that the difference in the genetic backgrounds of
these mice as well as the difference in the transgenic V� elements expressed may
affect the final outcome.
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Anergy in murine T cell clones: I. Lack of costimulation
T cell clonal anergy has been best described and characterized in work done with
murine IL-2 secreting (Th-1) T cell clones by Ronald Schwartz and his colleagues. In
initial experiments, Jenkins and Schwartz demonstrated that chemically fixing antigen
presenting cells with either paraformaldahyde or 1-ethyl-3-(3
dimethylaminopropyl) carbodiimide (ECOI), and then using these cells to present
peptide to T cell clones, would result in a long lasting state of anergy (103). It was
later found that the addition of unfixed allogeneic antigen presenting cells (which
themseves could not present the peptide) to the fixed syngeneic cells and peptide would
induce proliferation and not anergy in the T cell clones (104). This work suggested
that the fixed cells could present the peptide, but that another essential signal
(present on the unfixed allogeneic cells) was destroyed by fixation.
In a more physiological model, Quill and Schwartz demonstrated that planar
membranes pulsed with peptide would also induce long term anergy in T cell clones
(44). This further suggested that a second or costimulatory signal was required to
induce proliferation in T cell clones. The planar membrane plus peptide was able to
induce partial activation of the cloned T cells as determined by an increase in cell
volume and interleukin-3 (but not IL-2) production. Factors that blocked this partial
activation, such as mAb to MHC class II molecules, also blocked the subsequent anergy.
More recently it has been shown that anergy can also be induced by treating T cell
clones with either Con A (105) or anti-C03 mAb (106) in the absence of accessory
spleen cells. Thus it appears that the engagement of the T cell receptor in the absence
of a costimulatory signal may lead to anergy. This costimulatory signal has recently
been determined to be a C028 ligand as antibodies to this molecule prevent the
induction of anergy in T cell clones treated with fixed antigen presenting cells and
peptide (107).
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Mechanism of anergy induction in T cell clones
Decreased I L-2 production appears to be the major defect in anergic T cell clones;
the addition of exogenous IL-2 reverses anergy (108) although it does not prevent its
induction (44). Experiments with cycloheximide have suggested that protein synthesis
is required for anergy induction (44). A rise in intracellular calcium levels also
appears to be essential as the calcium chelator EGTA blocks anergy induction (109),
ionomycin by itself can anergize T cell clones (109), and anergy can be prevented by
cyclosporin A (110), a drug that, among other things inhibits the
calcium/calmodulin/calcineurin pathway (81).
The exact molecular defect present in anergic cells has not been determined
although some progress has been made. Engagement of the T cell receptor normally
results in the activation of several tyrosine kinases including p5Slck and p59fyn. The
enzyme phospholipase C is activated by this tyrosine phosphorylation and this results
in the hydrolysis of phosphatidyl inositol bisphosphate into 1,4,5 trisphosphate,
which produces an increase in intracellular calcium, and diacylglycerol which
activates protein kinase C. These two signals then activate several factors that initiate
transcription of the IL-2 gene. However, additional signalling through the CD28
coreceptor is required for optimal IL-2 production.
Some studies suggest that anergized T cell clones can mobilize calcium normally in
response to T cell receptor ligation (111), but other investigators have found anergic
cells to be defective in calcium flux and phosphatidylinositol hydrolysis (112).
Recently it has been shown that anergized T cell clones express decreased levels of
p5SIck (113) and increased levels of p59fyn (113,112) in response to stimulation.
Interestingly, when anergy is reversed with IL-2, the clones express normal levels of
both kinases (113). Furthermore a decrease in the tyrosine phosphorylation levels of
two uncharacterized proteins, p38 and p71 is seen (114). This is particularly
interesting as the same pattern is seen in T cells from V�8.1 TCR transgenic mice
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tolerized in vivo with Mls-1 a spleen cells (102). This might suggest that the types of
anergy have similar mechanisms.
Go and Miller have looked at the at the pattern of transcription factors associated
with the I L-2 promoter in untreated and anergic T cell clones. They found that during
the inductive phase of anergy (using fixed antigen presenting cells and peptide),
neither NF-AT nor one of the NFKB binding factors (NF-KB-B2) was induced (116).
In contrast, when the anergized cells were stimulated with peptide and competent
antigen presenting cells, normal levels of all the factors associated with IL-2
transcription (NF-AT, AP-1, Oct-1, Oct-2, NF-KB-B1, and NF-KB-B2) were
induced, yet the cells secreted very little IL-2 (116). Kang et al. used a
chloramphenicol acetyl transferase assay to demonstrate that the AP-1 complex in
anergic cells failed to transactivate the phorbol response element of the IL-2
promoter (117). When anergy was reversed with IL-2, normal AP-1 transactivation
occured. Gel shift assays showed that significant levels of AP-1 were induced in
stimulated anergic cells implying that the defect was due to poor binding of the
transcription factor to the promotor (117). The exact mechanism has not been
defined.
Anergy in murine T cell clones II: Activation in the absence of IL-2
Anergy can also be induced in Th-1 T cell clones if the autocrine response to IL-2 is
blocked. In one such study, T cells were activated with competent antigen presenting
cells and peptide, but were prevented from proliferating by the addition of
neutralizing anti IL-2 mAb and blocking mAb against the IL-2 receptor. This
treatment anergized the cells (118). In a similar experiment, partial anergy was
induced if IL-2 was washed out of activated T cell cultures (119).
Anergy in murine T cell clones III: Partial activation with peptide analogues
In a more recent model, Sloan-Lancaster et. al. have shown that peptide analogues
can anergize T cell clones (120). T cell clones specific for hemoglobin were
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inactivated when they interacted with competent antigen presenting cells and a
hemoglobin peptide that had a single amino acid substitution. Similar to the work done
with planar membranes (44), it was shown that while the analogue peptide could not
induce proliferation or cytokine secretion, it could partially activate the T cell as
determined by an increase in cell volume and increased expression of LFA-1 and the
IL-2 receptor. It also appeared that this partial activation was necessary for the
subsequent anergy as analogue peptides that could not partially activate the cells did
not induce anergy. Cyclosporin A could prevent anergy induction in this system, an
interesting observation as this drug also prevents anergy induced by fixed cells and
peptide (110).
Taken together, all three models of anergy (lack of costimulation, blocking the
autocrine IL-2 response, activation with analogue peptides) in murine T cell clones
have a common theme, partial activation in the absence of proli.feration resulting in
subsequent nonresponsiveness. Jenkins (121) has explained the first two models by
hypothesizing that partial activation results in the synthesis (or modification) of an
inhibitory protein (or proteins) that is diluted out only when the cell proliferates in
response to IL-2. If proliferation does not occur, then the inhibitory protein will
prevent the full activation of the cell in response to subsequent stimuli. Cleary this
explanation can be extended to the third model (activation with peptide analogues) as
well but it does not explain why the addition of IL-2 does not prevent the induction of
anergy in the first model.
Relevance of anergy in T cell clones to primary T cell anergy
Whereas the work with T cell clones has led to a better understanding of the
mechanisms involved in tolerance, it is not clear how relevant work with T cell clones
is to tolerance in primary T cells. However, it has been recently shown that
immobilized anti CD3 induces anergy in highly purified resting T cells in vitro. After
treatment, these cells neither proliferate nor secrete IL-2 in response to
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restimulation with the mAb (122). The addition of exogenous IL-2 did not prevent the
induction of anergy but interleukin-4 (IL-4) prevented anergy and induced the
differentiation of these cells into IL-4 (but not IL-2) secreting Th-2 like cells
(122). This corresponded with work showing that Th-1 but not Th-2 T cell clones
could be anergized with anti CD3 mAb (122). The investigators did not address the
question of whether IL-2 could reverse anergy in primary T cells.
The engagement of the T cell receptor in the absence of costimulation does not always
anergize primary T cells. In a recent study, purified naive CD4+ T cells from pigeon
cytochrome c specific a� TCR transgenic mice were incubated with immobilized MHC
class II molecules and the specific antigen (123). The cells did not secrete IL-2 in
response to this stimulus but they expressed the IL-2 receptor suggesting that they
were partially activated. In contrast to the finding with T cell clones, this partial
activation did not lead to subsequent anergy as the cells could later be fully activated if
they were given adequate costimulation (123).
Corresponding to the conclusions of in vitro work discussed above, several in vivo
studies suggest that immunization with antigen in the absence of costimulation leads to
tolerance. Jenkins and Schwartz demonstrated that the intravenous injection of mice
with peptide crosslinked to fixed antigen presenting cells would prevent the
subsequent activation of T cells when the animals were primed with the same antigen
and CFA (103). Furthermore in the mouse experimental allergic encephalomyelitis
(EAE) model (where mice immunized with MBP and CFA develop an autoimmune
disease similar to multiple sclerosis) Miller et al. (124) showed that injecting mice
with myelin basic protein (MBP) coupled to fixed antigen presenting cells prevented
disease when the mice were later primed with MBP and CFA. Another group has shown
that the injection of mice with soluble MHC proteins complexed to encephalitogenic
MBP peptides prevents the induction of EAE when the mice are challenged with the
same peptides emulsified in CFA (125).
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As mentioned earlier, CD28 has been found to be involved in the costimulation
pathway. Its ligand is probably 87, a molecule found on activated 8 cells(126) and
macrophages (127) and expressed on mature splenic dendritic cells (128). CTLA-4,
(129) a molecule found on activated T cells (130) is also involved with costimulation
and also interacts with the 87 protein (129). CTLA4Ig, a soluble form of CTLA-4,
blocks the interaction between CD28/CTLA4 and 87 (129). Lenschow et al. were able
to induce specific tolerance to xenogenic islet transplants if the recipient mice are
simultaneously treated with CTLA41g (131). This molecule, however, can induce only
short term acceptance of cardiac allografts in rats (132).
While these studies demonstrate that lack of costimulation can lead to tolerance in
vivo, the difficulty of determining whether or not potentially self reactive T cells are
present has left unresolved the question of whether anergy is actually the mode of
tolerance.
Relevance of anergy in T cell clones to superantigen induced anergy
It appears that the partial activation model cannot readily be used to explain
superantigen induced tolerance. To the best of our knowledge, there are no in vitro
models of superantigen induced tolerance in murine T cell clones. A.E7, the pigeon
cytochrome c (PCC) specific T cell clone used for many of the initial experiments is
Vf33+ and should therefore be reactive to the bacterial superantigen SEA as well as to
PCC. It would be interesting to make planar membranes in order to compare the ability
of SEA and PCC to induce anergy especially since a rise in intracellular calcium
appears to be necessary for anergy induction (109,110) and there have been studies
suggesting that superantigens do not induce a calcium flux in T cell clones (98,100).
It is also clear that superantigens induce full and not partial activation of T cells in
vivo. They clearly induce proliferation as superantigen administration results in an
initial expansion of superantigen reactive T cells (69,72,73). Superantigens also
induce cytokine secretion from T cells as serum IL-2 and TNF levels rise dramatically
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within an hour of SEB injection (133) and in situ hybridization studies have localized
mRNA for these cytokines to the T cell dependent regions of the spleen (134). Thus the
mechanism of superantigen mediated tolerance induction in vivo appears to be
fundamentally different from the mechanism of anergy induction in T cell clones in
vitro.
How do superantigens tolerize mature T cells?
It is still not known why superantigens tolerize mature T cells, although several
hypotheses have been proposed. Some light has been shed on this by results obtained in
two different systems. When thymectomized Mis 1- (Mls1 b) mice were inoculated
with spleen cells from Mis 1 + (Ms1 a) mice, there was an initial phase of clonal
expansion of T cells bearing the Mls-1 reactive V�6 segment as part of their receptor.
These V�6+ cells were then largely deleted and the remaining cells did not respond
well to Mls1 a stimulator cells in vitro (69). Webb et at, proposed the exhaustive
differentiation hypothesis based on this work with Mis suggesting that tolerance could
be the result of a "powerful" in vivo immune responses.
Work involving TCR transgenic mice specific for the HY (male) antigen has provided
another model for peripheral tolerance. CDB T cells in these mice recognize the HY
antigen in the context of Db and thus proliferate in response to male but not female H-
2b spleen cells. Cells bearing transgenic TCRs are tolerized in male mice but are
functional in females (135). When mature naive T cells were taken from female
transgenic mice and injected into male nude mice, a phase of clonal expansion followed
by unexpected deletion was seen (136). The remaining cells had downregulated levels
of TCR and COB, and responded poorly when challenged with HY+ spleen cells in vitro.
The kinetics of this process were remarkably similar to that seen with SEB (72,73)
and Mis (69) primed mice, and the results are consistent with the exhaustive
differentiation hypothesis that a powerful in vivo immune response could eventually
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lead to tolerance. As the HY antigen is not a superantigen, the tolerance seen in this
system suggested that exhaustive differentiation might be a global phenomenon.
Our present results suggest that a prolonged immune response in vivo does not
necessarily lead to tolerance. No major changes were seen in the number of KJ1-26+
cells when 0011.10 mice were primed with OVA 323-339. Cells from these mice
could respond normally to SEB and to crosslinking of their T cell receptors and were
hyperresponsive to OVA 323-339 and ovalbumin. While we have only immunized mice
with one dose and looked at one time point, it is still noteworthy that we got a memory
type response as treating mice with doses of SEB ranging from as low as 1 ug (70) to
as high as 1 mg (71) has always resulted in tolerance and not immunity. Diminished
responses are seen even during the clonal expansion phase despite the marked increase
in the number of superantigen reactive cells (69, and our own unpublished
observations). The development of memory rather than tolerance in response to
priming with OVA peptide suggests that exhaustive differentiation alone probably
cannot explain SEB induced tolerance. However, in a recent study it was shown that
treating preactivated transgenic LN cells with very high doses of specific peptide in
vivo (3.2 mg LV. over a period of 7 days) results in clonal deletion (115). Thus it is
possible (though not likely) that very high doses of OVA emulsified in CFA would
induce high zone tolerance. It is also possible that very low doses «1 ug) of SEB might
induce a memory response.
Another hypothesis proposes that memory cells are inherently non responsive to
superantigens and that SEB induced anergy can be largely explained by either the
selective deletion of SEB reactive virgin T cells, or the differentiation of SEB reactive
naive cells into SEB non responsive memory T cells (137). If superantigen induced
tolerance could be fully explained by non responsiveness of memory T cells to
superantigens, then one would expect cells from SEB primed 0011.10 mice to respond
normally to OVA 323-339 and/or to native ovalbumin; there is no obvious reason why
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memory T cells should be anergic to conventional antigens. One might also expect cells
from OVA primed 0011.10 mice to be anergic to SEB since memory cells are clearly
formed. The fact that cells from SEB primed mice are hypo responsive to both
conventional antigen and superantigens, combined with the fact that cells from OVA
primed mice respond normally to SEB, would make the hypothesis of memory cell
unresponsiveness unlikely to be the sole explanation of SEB induced anergy.
A third hypothesis stems from a study showing that B cells induce tolerance in virgin
T cells in vivo (138). It was proposed that SEB induced tolerance could be the result of
the superantigen's ability to bind directly to MHC class II molecules without prior
processing. This feature, it was argued, would predispose SEB to B cell presentation
since B cells far outnumber professional antigen presenting cells. This B cell
presentation would then result in tolerance. Peptides like superantigens can bind
directly to surface MHC class II molecules. If superantigen induced tolerance is due to
selective B cell presentation, then priming with OVA 323-339 should lead to the same
outcome. This was not the case as immunity and not tolerance was seen when mice were
primed with the peptide. Thus B cell presentation alone apparently cannot explain the
tolerance seen in our system.
It is possible however, that superantigens bind to surface MHC class II proteins on B
cells with a much higher affinity than do peptides especially at high doses. Philip
Leder's laboratory has recently developed B cell deficient transgenic mice (139).
These mice could be used to definitively address the role of B cells in superantigen
mediated tolerance. We are currently breeding these mice and plan to test them (in
comparison with non transgenic mice) after priming with SEA in order to compare the
degree of tolerance in the groups of mice.
It would also be interesting to determine whether dendritic cells, which when pulsed
with small quantities of superantigens are potent T cell activators in vitro (140),
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would be able to induce tolerance in mature T cells in vivo. This could be done by
pulsing dendritic cells with SEB or OVA and injecting them into 0011.10 mice.
What does anergy mean in vivo?
Superantigen induced anergy has been mostly characterized by in vitro proliferation
and IL-2 secretion assays. A recent study has suggested that the degree of anergy seen
in vitro might not necessarily be indicative of the in vivo response. The investigators
tolerized mice with SEB and compared the serum IL-2 levels of control vs tolerant
mice in response to SEB restimulation. The tolerized mice produced only 3-5 fold less
IL-2 in vivo. In contrast, cells from these mice produced 20-50 times less IL-2 in
vitro than control cells. This suggested that the cells were more tolerant in vitro than
in vivo (141).
Bandiera et at, have argued that the lack of a proliferative response in Mls-1 a
tolerized mice does not correlate with in vivo tolerance (142). The investigators
found that anergized V�6 T cells from Mls-1 b mice tolerized with Mls-1 a spleen cells
were capable of inducing the differentiation of donor Mls1-a B cells into
immunoglobulin secreting plasma cells in vitro and in vivo. In addition, anergic T cells
appeared to have aquired memory status as they were better able to mediate the
rejection of donor Mls-1 a B cells in vivo. It was argued that rather than the cells
being anergic, they had differentiated into T helper cells whose effector functions
included providing help to 8 cells but not I L-2 secretion or proliferation.
In contrast to this finding, Lussow and MacDonald have recently demonstrated that
V�8.2 TCR transgenic mice tolerized with SEB produce significantly lower antibody
titers than control transgenic mice when immunized and boosted with tetanus toxoid
(94). Thus it appears that at least in this model, T cells were functionally anergic in
vivo as well as in vitro.
It would be very interesting to study anergy in vivo with the recently developed MBP
specific a� TCR transgenic mouse (143). T cells from these mice express V�8.2 as
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part of their receptor and should therefore respond to SEB as well as to MBP. T cells
from these mice are not tolerant and they develop EAE when their blood brain barriers
are transiently permeabilized with pertussis toxin (non transgenic mice develop EAE
only when they are immunized with MBP and CFA and given pertussis toxin). It would
be interesting to tolerize these mice with SEB and then determine if the anergic cells
are still capable of inducing EAE .
Significance of our model
This work, and the previously described study where HY reactive T cells were
adoptively transferred into male nude mice (136), are the only two models where a
monoclonal population of mature primary T cells have been anergized in vivo. There
are other models where TCR transgenic mouse mice were crossed to mice positive for
the specific antigen and this generally leads to tolerance in the F1 mice. However the T
cell developed in the presence of the "self" antigen and were probably tolerized before
they completed development. Our model and the HY antigen model differs from these
other models in that mature T cells were tolerized. This is important because Yui et aJ.
have demonstrated that there might be different mechanisms involved in the tolerance
of mature and immature T cells (101). It was shown that when T cells from V�8.1 TCR
transgenic mice were tolerized at an early stage (by breeding the mice on an Mls-1 a
background), they could neither mobilize calcium nor proliferate in response to anti
TCR mAbs. On the other hand, when T cells from the same mice were tolerized after
they had fully matured (by treating the mice with Mls-1 a spleen celis), they could
mobilize calcium but not proliferate in response to the same stimulus. The mechanism
involved in tolerizing mature T cells is less well understood but will probably be more
relevant to designing specific treatments to combat autoimmune disease and transplant
rejection.
In summary, we have demonstrated that when these antigens are emulsified in CFA and
are then injected subcutaneously, superantigens and conventional antigens behave very
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differently. SEB tolerizes mature T cells whereas OVA peptide induces memory. We
feel that this dramatic difference in outcome is most likely due to differences in the
signal transduction pathways coupled to the two classes of antigens. The differences
between these pathways need to be carefully examined. If superantigens utilize a
system that eventually leads to tolerance, then it might be possible to design agents
that selectively activate this pathway. Such agents might be useful in treating
allergies, autoimmune disease, and transplant rejection.
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Chapter 2.1 (Introduction)
The mechanisms involved in T cell activation have been partially worked out.
Engagement of the T cell receptor results in initial activation of several tyrosine kinases
including p561ck and p59fyn. The enzyme phospholipase C is activated by tyrosine
phosporylation and this results in the hydrolysis of phosphatidyl inositol bisphosphate
into inositol 1,4,5 trisphosphate which produces an increase in intracellular calcium,
and diacylglycerol which activates protein kinase C. The two signals activate
transcription factors associated with the IL-2 promoter. However, additional signalling
through the CD28 coreceptor is required for optimal IL-2 production.
There have been several studies suggesting that superantigens and conventional antigens
activate different signal transduction pathways. We felt that these differences might best
explain why the interaction of T cells with the two sets of antigens resulted in different
outcomes.
Phosphatidyl inositol
O'Rourke et at, (97) first demonstrated differences in the signal transduction pathways
triggered by superantigens as opposed to. conventional antigens. The investigators
demonstrated that purified V�6 T cells that had been primed in vitro with Mls-1 a
stimulator cells would proliferate but not generate phosphatidyl inositol (PI) hydrolysis
in response to a secondary stimulation with Mls-1 a cells. The lectin Con A, on the other
hand, induced both proliferation and PI hydrolysis. In addition it was shown that
alloantigens but not Mis positive cells would trigger PI hydrolysis in a T cell clone and
hybridoma that could proliferate and secrete interleukin-2 (IL-2) in response to either
antigen.
Oyaizu et at, (100) have recently reported similar findings with a human T cell clone
that is specific for a conventional antigen (purified protein derivative, PPD) and a
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superantigen (SEB). It was found that PI hydrolsis was generated in response to PPD but
not to SEB.
In contrast to these findings, Fraser et al (144) reported that the bacterial
superantigen SED, when presented by the Raji B cell lymphoma cell line, would trigger
PI hydrolysis in the Jurkat T cell line. The level of hydrolysis seen in response to the
superantigen was comparable to that seen in response to anti TCR mAb. This was in
agreement with a prior study which demonstrated that the bacterial superantigen toxic
shock syndrome toxin 1 (TSST-1) was capable of inducing inositol phospholipid
turnover in human peripheral blood mononuclear cells (145).
Calcium flux
Liu et al used mouse T cell clones that were specific for both a conventional antigen
(OVA) and a superantigen (SEB) in calcium flux assays and concluded that T cells would
mobilize calcium in response to stimulation with conventional antigens but not
superantigens (98). This work has been confirmed by another group using human T cell
clones specific for PPD and SEB (100). On the other hand, several studies have shown
that primary mouse T cells can mobilize calcium in response to Mis antigens
(101,146).
CD4
Oyaizu et at, used dual specific T cell clones to demonstrate that that low concentrations
of anti-CD4 mAb would inhibit proliferation, IL-2 secretion, and IL-2 receptor
expression in response to PPD but not to SEB (100). This supported a prior finding that
CD4 deficient hybridomas could respond as well as CD4 transfectants to a panel of
bacterial superantigens (147). Recently, however Bhardwaj et at, have found that anti­
CD4 mAbs would inhibit the proliferative response of primary human T cells in response
to superantigen pulsed dendritic cells (140).
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Cytokine secretion
Using murine T cells specific for OVA and SE8, Liu et al. (98) demonstrated that
conventional antigens stimulated the secretion of 5-15 fold higher levels of interleukin-
3 (IL-3) and IL-2 than superantigens although the two sets of antigens induced similar
levels of proliferation. Prior to this the same group showed that conventional antigens
but not superantigens would induce transcription of the interferon-y gene (99). Our own
work with primary 0011.10 T cells indicates that IL-2 secretion is induced by SE8 as
well as by OVA 323-339.
Antigen presentiation
Roth et al. (148) recently demonstrated that MHC class II positive astrocytes would
present peptide antigen but not superantigens to rat T cell lines. In contrast, bulk
thymocytes (which contained dendritic cells) could present both sets of antigens
efficiently. It was also shown that macrophages but not astrocytes could present a panel of
bacterial toxins to primary mouse T cells. FACS analysis was used to show that the
astrocytes were capable of binding the superantigens and it was also shown that they
could present superantigen and induce IL-2 secretion in T cell hybridomas. This work
suggested that superantigen induced activation required a unique costimulatory
molecule(s) that was not present on astrocytes.
C028/87(881 )
The ligand(s) for the C028 receptor (most likely the 87/881 molecule) is the best
defined costimulatory molecule for conventional antigens. In reconstitution experiments,
Harding et al. showed that immobilized anti-C03 mAb by itself would not activate highly
purified CD4 T cells (107). The addition of either 8 cell blasts or anti-CD28 mAb to
this system would induce proliferation. Importantly, it was shown that the major
costimulatory molecule on the 8 cell blasts was the CD28 ligand as the addition of anti
C028 Fab fragments completely blocked the 8 cell derived costimulation.
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In a somewhat more physiological model, Sagerstrom et al. (123) have recently shown
that immobilized MHC class II molecules and peptide would not activate IL-2 secretion T
cells from moth cytochrome c specific 0.13 TCR transgenic mice. The addition of anti CD28
mAb to this system resulted in activation as determined by IL-2 secretion.
There have been conflicting reports on the role of the CD28/B7 pathway in
superantigen induced activation. Fraser et. al recently demonstrated that CD28
costimulates SED induced IL-2 secretion in primary human and Jurkat T cells (144).
The T cells were transiently transfected with a reporter gene linked to either the wild
type I L-2 promoter or an I L-2 promoter with a mutation in the CD28 response element.
The mutated promoter responded as well as the wild type promoter when transfected cells
were stimulated with either PMA and ionomycin or anti TCR mAbs. However, the mutant
promoter responded only 40% as well as the wild type promoter when transfected Jurkat
cells were stimulated with SED. In transfected primary T cells, the response of the
mutated promoter to a panel of bacterial toxins was only 20% of control suggesting that
the IL-2 response of primary T cells to superantigen was even more dependent on CD28
mediated costimulation. In addition, the addition of anti-B7 mAb to the superantigen
stimulated transfected cells blocked the activity of the wild type but not the mutated
promoter.
Ohnishi et al. showed that anti B7/BB1 mAb inhibited the proliferative response of
resting human T cells to the streptococcal superantigen pep MS presented by autologous
antigen presenting cells (149). Furthermore, crosslinking the CD28 molecule would
costimulate the response of purified T cells in response to pep MS in the presence of
antigen presenting cell derived culture supernatant. Recently Bhardwaj et al. have shown
that blocking mAbs to CD28 can inhibit proliferation of purified T cells by 80-90% in
response to dendritic cells pulsed with very small quantities of SEA (140). The system
used in this study is probably more physiological as very low doses of superantigen were
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used. It is also noteworthy that, under these conditions, other surface molecules such as
CD4 and LFA-1 contribute to superantigen induced activation.
In contrast to these findings, Damle et al. (150) reported that costimulation by 87 was
not neccessary for the proliferation of human T cells to SEA. Irrespective of whether they
were 87+ or 87-, MHC class II bearing cells could induce superantigen mediated
proliferation in resting or activated T cells. Moreover, CTLA4Ig, a reagent that binds
with high affinity to C028 ligands and can thus block 87/C028 mediated costimulation,
had no effect on proliferation or IL-2 secretion of T cells in response to superantigens
presented by 8 cell lines. This reagent efficiently blocked the response of T cells to
alloantigens presented by the same cells implying that 87/C028 mediated costimulation
was important in conventional antigen but not superantigen induced activation. In this
report however, mAbs to C011 a and C018 (LFA-1) blocked the proliferative response
of superantigens presented by various kinds of antigen presenting cells suggesting that
the LFA-1/ICAM interaction was essential for superantigen mediated activation. This
finding was confirmed by work by Nickoloff et at. (151) where mAbs to LFA-1 a, LFA-1 b
or ICAM-1, but not to 87 were shown to block the response of primary human T cells to
MHC class 11+ 87+ keratinocytes.
All these studies were done with human T cells and we were thus interested in
determining whether the C028/87 pathway played a role in the the response of primary
mouse T cells to superantigens. We felt this issue was particularly important as several
in vivo studies have suggested that occupation of the TCR in the absence of costimulation
leads to tolerance. Thus if the response to superantigens did not require C028, than this
might explain why these antigens tolerized mature T cell in vivo.
Our system offered certain advantages for addressing this issue. 0011.10 cells can
respond to SE8 as well as to OVA and we were thus able to compare the role of C028/87
mediated costimulation in the response of primary T cells to superantigens vs
conventional antigens. Two approaches were used in vitro. First we used a 8 cell line that
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expressed very low levels of the B7 antigen (TA3) and its B7 transfected derivative
(TA3-mB7) as antigen presenting cells. In addition we examined the effect of anti-CD28
mAb on the proliferative and IL-2 secretion response of D011.1 0 T cells to SEB vs OVA.
We found that either anti-CD28 mAbs or high levels of the B7 antigen would
costimulate the response of T cells to both SEB and OVA, suggesting that CD28/B7
costimulation plays a role in the signal transduction pathways coupled to either of the two
types of antigens.
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Chapter 2.2 (Results)
Expression of the 87 antigen
The 8 cell lymphoma line TA3 expresses very low levels of the 87 as shown in Figure
22. TA3-m87 was derived in the laboratory of Dr. Casey Weaver by transfecting the
TA3 cell line with the murine 87 gene (93). As shown in figure 22, TA3-m87 cells
express significantly higher levels of the B7 antigen than the TA3 parental cell line.
Figure 22 also shows that the two cell lines expressed comparable levels of the two MHC
class II genes, I-Ad and I-Ed. We compared these cells to the A20 B cell lymphoma line.
It was found that A20 cells also expressed very low levels of the B7 antigen and high
levels of the I-Ad and I-Ed MHC class II proteins.
Costimulation of the response of purified C04 cells to SEB or OVA
As shown in Figure 23, the proliferative response of purified 0011.10 C04 T cells to
both SEB and OVA 323-339 presented by the A20 cell line was substantially increased
by the addition of anti C028 mAbs. Notably, anti-CD28 Mab by itself had no effect on
0011.10 cells. Table IX demonstrates that anti-C028 mAb also increased the amount of
IL-2 secreted by the C04 cells in response to the two antigens presented by the A20
cells.
The addition of anti-CD28 mAb also increased the proliferative and IL-2 secretion
response to SEB and OVA 323-339 presented by TA3 cells (Fig. 23 and Table IX).
Presentation of SEB and OVA 323-339 by TA3-mB7 cells resulted in significantly
increased levels of proliferation (Fig. 23) and I L-2 secretion (Table IX) by 0011.10
C04 cells as compared to presentation by TA3 cells.
Costimulation o"f C08 T cell depleted spleen cells
The proliferative (Fig. 24) and IL-2 secretion (Table X) response of C08 T cell
depleted spleen cells to both SE8 and OVA 323-339 was increased by the addition of
anti-C028 mAb. This mAb by itself had no effect on the cells.
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Table IX. IL-2 secretion (U/ml) in response to OVA 323-339 (100 nM) or SEB
(1 ug/ml) with or without 10 ug/ml of anti-CD28 mAb presented by different antigen
presenting cells .
A20
A20 + anti-CD28
OVA 323-339 (100nM)
15
38
SEB (1 ug/ml)
26
126
TA3
TA3 + anti CD28
TA3-mB7
16
48
56
99
277
240
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Table X. IL-2 secretion by CD8 T cell depleted spleen cells in response to OVA 323-339
(100 nM) or SEB (1 ug/ml) with or without 10 ug/ml of anti-CD28 mAb .
Antigen alone
Antigen + anti-CD28
OVA 323-339
19
46
.sea
29
72
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I-A I-E
I
B7
Figure 22. FACS analysis of TA3 cells (A-C), TA3-mB7 cells (O-F) and
A20 cells (G­
I). Cells were stained with mAb to either lAd (A,O,G), lEd (B,E,H) or 87 (C,F,I).
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II-A I-E B7
Figure 22. FACS analysis of TA3 cells (A-C), TA3-mB7 cells (D-F) and A20 cells (G­
I). Cells were stained with mAb to either lAd (A,D,G), lEd (B,E,H) or B7 (e,F,I).
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Figure 23. Proliferation of purified CD4 cells from D011.10 transgenic mice in
response to OVA 323-339 (a.c) or SEB (b,d) presented by. A20 cells (a,b) TA3 cells
(c,d) or TA3-mB7 cells (c,d). Where indicated, anti-CD28 mAb was added at a
concentration of 10 ug/ml to each dose of antigen. Background counts «3200 CPM)
were subtracted. Anti-CD28 mAb by itself had no effect on the cells.
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Chapter 2.3 (Discussion)
The CD28 coreceptor was first recognized to have a costimulatory role in human T cells
when it was shown that mAbs to this molecule would increase the response of purified T
cells to PMA, PHA, anti CD3, or anti CD2 mAbs (152). Studies with a recently developed
mAb to mouse CD28 have confirmed that this receptor is involved in costimulation of
mouse T cells as well (107, 123).
The counter receptor for CD28 was shown to be B7 by an intercellular adhesion assay
using Chinese hamster ovary (CHO) cells transfected with the gene for CD28 (153).
This work was later confirmed by showing that CHO cells transfected with the 87 gene
were capable of costimulating the response of T cells to anti-CD3 mAb (154).
CTLA-4 has been identified as another receptor for 87 (129). This receptor is found
only on activated T cells and at much lower levels than CD28 (130). It however has a
much higher affinity for B7 (20 times higher than CD28). CTLA41g is a soluble reagent
formed from the fusion of the extracellular domain of the human receptor with an
immunoglobulin molecule (129). This reagent binds to mouse as well as human 87
molecules and blocks costimulation in both systems.
The previously described reconstitution experiments of Harding et al. (107) and
Sagerstrom et at, (123) strongly suggested that CD28 was the major costimulatory
molecule involved in mouse T cell activation. This has been confirmed in studies with the
recently developed CD28 knockout mice. When T cells from these animals are stimulated
with the lectin Con A, the proliferative and IL-2 secretion response is reduced by
roughly 80% compared to control T cells (155). The remaining partial response,
however, indicates that the signal transmitted through the CD28 coreceptor is not
absolutely required for T cell activation (at least in response to Con A).
Recent studies have suggested that there is more than one counter receptor for CD28.
Transgenic mice deficient for the 87 gene have been developed (156) and FACS analysis
has shown that 8 cells from these mice still react with CTLA4Ig. In addition, 8 cells from
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these mice could elicit a somewhat reduced allogeneic MLR response which could be
partially blocked with CTLA4Ig. This work strongly suggested that there was another
CD28/CTLA-4 ligand on B cells.
Hathcock et al, generated a mAb (GL1) that stained activated mouse B cells and
inhibited the binding of CTLA41g to these cells but did not react with B7 transfected CHC'
cells (157). Furthermore, this mAb partially inhibited the ability of activated B cells
to costimulate the response of purified T cells to anti CD3 mAb. It was also shown that
this mAb stained B cells from B7 deficient mice (156) but it has not been determined
whether this reagent will block the ability of B7 deficient B cells to elicit an allogeneic
response.
As outlined in the introduction, there have been conflicting reports on the ability of the
CD28/B7 pathway to costimulate the response of T cells to superantigens. We therefore
used primary T cells from D011.10 mice, that could react to both OVA and SEB, to
address this issue. We found that the ability of A20 cells to present both SEB and OVA was
enhanced by the addition of anti-CD28 mAbs; proliferation as well as IL-2 secretion in
response to both antigens was significantly increased. Anti-CD28 mAbs also had a
costimulatory effect on the response of D011.1 0 T cells to both OVA and SEB presented
by the TA3 cell line. The presence of increased levels of the B7 antigen on TA3-mB7
cells also costimulated the response to the two antigens. The limited response to antigens
presented by the low B7 expressing A20 and TA3 cell lines in the absence of anti-CD28
mAb might be due to costimulation with the recently described GL1 ligand (157).
It is important that the addition of anti-CD28 mAb to TA3 cells mimicked the enhanced
response of T cells to antigen presented by the TA3-mB7 cell line. This implies that the
increased proliferative response to these cells was due to costimulation and not just an
increase in the adhesion between responder cells and the transfected cell line.
Anti-CD28 mAbs also costimulate the the response of CD8 T cell depleted spleen cells
in response to both antigens. The response seen in the absence of the mAb is probably
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solely due to presentation by mature splenic dendritic cells which express high levels of
MHC class II molecules and express a CD28/ CTLA-4 counter receptor {128}. The CD28
mAb is most likely costimulating the response of T cells to antigen presented by resting
B cells which express MHC class II but not B7 (126) nor the GL1 ligand (155).
We felt it was important to address the issue of the role of CD28 mediated
costimulation in the response to superantigens since there have been several studies
suggesting that engaging the T cell receptor in the absence of costimulation results in
tolerance in vivo (1 03,124,125,131). In particular, It has been shown that treating
mice with CTLA41g induces specific tolerance to xenogeneic transplants {131}. In
addition it has been shown that blocking a human MLR reaction with CTLA41g (158) in
vitro induces tolerance to the alloantigens. It is not known why superantigens tolerize
mature T cells in vivo; the ability of these antigens to stimulate T cells without CD28
mediated costimulation might provide an explanation for this outcome.
We have clearly shown that the CD28/B7 pathway costimulates the response to
superantigens as well as conventional antigens. We have however not addressed the
question of whether superantigens can stimulate T cells in the complete absence of CD28
mediated costimulation. CD28 deficent mice {155} or better still CD28 and CTLA4
deficient mice should be used for this purpose. These mice can be mated to D011.1 0 mice
and the response of T cells from these D011.10, CD28 deficient mice to OVA and SEB
compared. It would also be interesting to immunize mice with the two types of antigens
and determine whether anergy or memory occurs in response to either antigen.
Another way to address this question would be to do. reconstitution experiments similar
to that of Sagerstrom et at, (123). Primary D011.10 T cells can be incubated with
purified MHC class II molecules complexed to either OVA 323-339 or to SEB. The
ability of the cells to respond to the two types of antigens in the presence or absence of
mAbs to anti-CD28 or to other putative costimulatory molecules such as LFA-1 can then
be compared. In summary we feel that understanding the differences involved in the
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signal transduction pathways coupled to the two sets of antigens will eventually lead to an
understanding of why in vivo immunization with conventional antigens generally leads to
memory whereas immunization with superantigens eventually leads to tolerance.
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